{ "source": "Graded", "licence": "CC BY 4.0, https://creativecommons.org/licenses/by/4.0/", "generated": "2026-11-03", "substances": [ { "slug": "5-amino-1mq", "url": "https://graded.pl/substances/5-amino-1mq", "names": { "primary": "5-amino-1MQ", "primary_pl": "5-amino-1MQ", "aliases": [ "5-amino-1-methylquinolinium", "NNMT inhibitor" ] }, "class": "metabolic-modulator", "lifecycle": "preclinical", "status": "draft", "summary": { "en": "A small molecule, not a peptide, that blocks a metabolism enzyme (NNMT). There are three scientific papers and no study in people.", "pl": "Mała cząsteczka, nie peptyd, która blokuje enzym przemiany materii (NNMT). Istnieją trzy prace naukowe i żadnego badania na ludziach." }, "last_reviewed": null, "wada": { "status": "s0-risk", "class": null, "list_year": 2026, "source": "https://zoek.officielebekendmakingen.nl/trb-2026-25.html" }, "safety": "unknown", "risk_of_fakes": "unknown", "grades": [ { "goal": "fat-loss", "grade": "D", "direction": "unclear", "modifiers": [], "studies": [ "pmid:35013352" ], "reason": { "en": "Weight and fat fell in obese mice. There are three papers and no study in people.", "pl": "Masa i tłuszcz spadły u otyłych myszy. Istnieją trzy prace i żadnego badania na ludziach." } } ], "legal": [ { "where": "PL", "status": "unauthorized", "summary": { "en": "The European medicines database (EMA) lists no such medicine in Poland (9 October 2026). The Polish register was down, so we could not check it directly.", "pl": "W europejskiej bazie leków EMA nie ma takiego leku w Polsce (stan na 9 października 2026). Polski rejestr nie działał, więc nie sprawdziliśmy tego bezpośrednio." }, "source": "https://www.ema.europa.eu/en/documents/other/article-57-product-data_en.xlsx", "checked": null }, { "where": "EU", "status": "unauthorized", "summary": { "en": "The European medicines database (EMA), which covers EU and national approvals, lists no such medicine (9 October 2026).", "pl": "W europejskiej bazie leków EMA, która obejmuje pozwolenia unijne i krajowe, nie ma takiego leku (stan na 9 października 2026)." }, "source": "https://www.ema.europa.eu/en/documents/other/article-57-product-data_en.xlsx", "checked": null }, { "where": "US", "status": "unauthorized", "summary": { "en": "The FDA drug register has no such medicine.", "pl": "W rejestrze leków FDA nie ma takiego leku." }, "source": "https://www.accessdata.fda.gov/scripts/cder/daf/", "checked": null } ], "research_counts": { "pubmed": 3, "pubmed_random_groups": 0, "clinicaltrials_gov": 0, "as_of": "2026-11-01T00:00:00.000Z" } }, { "slug": "aicar", "url": "https://graded.pl/substances/aicar", "names": { "primary": "AICAR", "primary_pl": "AICAR", "aliases": [ "acadesine", "AICA riboside" ] }, "class": "metabolic-modulator", "lifecycle": "investigational", "status": "draft", "summary": { "en": "A small molecule, not a peptide, that switches on an enzyme controlling energy in cells (AMPK). Mostly a lab tool. No such medicine exists.", "pl": "Mała cząsteczka, nie peptyd, która uruchamia enzym sterujący energią w komórkach (AMPK). Służy głównie w laboratoriach. Nie ma takiego leku." }, "last_reviewed": null, "wada": { "status": "prohibited", "class": "S4.4.1", "list_year": 2026, "source": "https://zoek.officielebekendmakingen.nl/trb-2026-25.html" }, "safety": "partial", "risk_of_fakes": "unknown", "grades": [], "legal": [ { "where": "PL", "status": "unauthorized", "summary": { "en": "The European medicines database (EMA) lists no such medicine in Poland (9 October 2026). The Polish register was down, so we could not check it directly.", "pl": "W europejskiej bazie leków EMA nie ma takiego leku w Polsce (stan na 9 października 2026). Polski rejestr nie działał, więc nie sprawdziliśmy tego bezpośrednio." }, "source": "https://www.ema.europa.eu/en/documents/other/article-57-product-data_en.xlsx", "checked": null }, { "where": "EU", "status": "unauthorized", "summary": { "en": "The European medicines database (EMA), which covers EU and national approvals, lists no such medicine (9 October 2026).", "pl": "W europejskiej bazie leków EMA, która obejmuje pozwolenia unijne i krajowe, nie ma takiego leku (stan na 9 października 2026)." }, "source": "https://www.ema.europa.eu/en/documents/other/article-57-product-data_en.xlsx", "checked": null }, { "where": "US", "status": "unauthorized", "summary": { "en": "The FDA drug register has no such medicine.", "pl": "W rejestrze leków FDA nie ma takiego leku." }, "source": "https://www.accessdata.fda.gov/scripts/cder/daf/", "checked": null } ], "research_counts": { "pubmed": 2552, "pubmed_random_groups": 12, "clinicaltrials_gov": 5, "as_of": "2026-11-01T00:00:00.000Z" } }, { "slug": "aod-9604", "url": "https://graded.pl/substances/aod-9604", "names": { "primary": "AOD-9604", "primary_pl": "AOD-9604", "aliases": [ "hGH 176-191", "Tyr-hGH(177-191)" ] }, "class": "peptide", "lifecycle": "abandoned", "status": "draft", "summary": { "en": "A changed fragment of human growth hormone, developed as an obesity drug. No such medicine exists, and there are no studies with random groups.", "pl": "Zmieniony fragment ludzkiego hormonu wzrostu, rozwijany jako lek na otyłość. Nie ma takiego leku ani badań z losowaniem grup." }, "last_reviewed": null, "wada": { "status": "prohibited", "class": "S2.2.3", "list_year": 2026, "source": "https://zoek.officielebekendmakingen.nl/trb-2026-25.html" }, "safety": "unknown", "risk_of_fakes": "moderate", "grades": [ { "goal": "fat-loss", "grade": "D", "direction": "unclear", "modifiers": [], "studies": [ "pmid:11146367" ], "reason": { "en": "Obese rats gained less weight. There are no studies with random groups in people.", "pl": "Otyłe szczury przybierały mniej na masie. Nie ma badań z losowaniem grup na ludziach." } } ], "legal": [ { "where": "PL", "status": "unauthorized", "summary": { "en": "The European medicines database (EMA) lists no such medicine in Poland (9 October 2026). The Polish register was down, so we could not check it directly.", "pl": "W europejskiej bazie leków EMA nie ma takiego leku w Polsce (stan na 9 października 2026). Polski rejestr nie działał, więc nie sprawdziliśmy tego bezpośrednio." }, "source": "https://www.ema.europa.eu/en/documents/other/article-57-product-data_en.xlsx", "checked": null }, { "where": "EU", "status": "unauthorized", "summary": { "en": "The European medicines database (EMA), which covers EU and national approvals, lists no such medicine (9 October 2026).", "pl": "W europejskiej bazie leków EMA, która obejmuje pozwolenia unijne i krajowe, nie ma takiego leku (stan na 9 października 2026)." }, "source": "https://www.ema.europa.eu/en/documents/other/article-57-product-data_en.xlsx", "checked": null }, { "where": "US", "status": "unauthorized", "summary": { "en": "The FDA drug register has no such medicine.", "pl": "W rejestrze leków FDA nie ma takiego leku." }, "source": "https://www.accessdata.fda.gov/scripts/cder/daf/", "checked": null } ], "research_counts": { "pubmed": 22, "pubmed_random_groups": 0, "clinicaltrials_gov": 0, "as_of": "2026-11-01T00:00:00.000Z" } }, { "slug": "bpc-157", "url": "https://graded.pl/substances/bpc-157", "names": { "primary": "BPC-157", "aliases": [ "Body Protection Compound 157", "PL 14736", "pentadecapeptide BPC 157" ] }, "class": "peptide", "lifecycle": "investigational", "status": "draft", "summary": { "en": "A synthetic peptide popular for injuries. Only three studies in people exist, 30 people in total, none with a comparison group. No such medicine exists.", "pl": "Syntetyczny peptyd popularny przy urazach. Istnieją tylko trzy badania na ludziach, łącznie 30 osób, wszystkie bez grupy porównawczej. Nie ma takiego leku." }, "last_reviewed": null, "wada": { "status": "prohibited", "class": "S0", "list_year": 2026, "source": "https://www.wada-ama.org/en/prohibited-list" }, "safety": "unknown", "risk_of_fakes": "high", "grades": [ { "goal": "recovery", "grade": "D", "direction": "unclear", "modifiers": [ "very-low-certainty", "no-human-rct" ], "studies": [ "pmid:34324435", "pmid:42542926" ], "reason": { "en": "Only uncontrolled reports in people, rated very unreliable. Mostly studies in rats and mice.", "pl": "Tylko opisy u ludzi bez grupy porównawczej, oceniane jako bardzo niepewne. Głównie badania na szczurach i myszach." } } ], "legal": [ { "where": "PL", "status": "unauthorized", "summary": { "en": "No approval. Polish health inspectors warn that synthetic peptides sold as research chemicals are not medicines and selling them is illegal.", "pl": "Brak pozwolenia. Główny Inspektorat Sanitarny i Główny Inspektorat Farmaceutyczny ostrzegają, że syntetyczne peptydy sprzedawane jako „odczynniki” nie są lekami, a ich sprzedaż jest nielegalna." }, "source": "https://www.gov.pl/web/psse-bochnia/ostrzezenie-publiczne-nielegalny-obrot-syntetycznymi-peptydami-oferowanymi-jako-odczynniki-chemiczne-lub-do-badan", "checked": null }, { "where": "EU", "status": "unauthorized", "summary": { "en": "The European medicines database (EMA), which covers EU and national approvals, lists no such medicine (9 October 2026).", "pl": "W europejskiej bazie leków EMA, która obejmuje pozwolenia unijne i krajowe, nie ma takiego leku (stan na 9 października 2026)." }, "source": "https://www.ema.europa.eu/en/documents/other/article-57-product-data_en.xlsx", "checked": null }, { "where": "US", "status": "unauthorized", "summary": { "en": "No approved medicine. On 30 October 2026 the US health department (HHS) published a draft policy: it does not plan to act against pharmacies and doctors that make it on a prescription for a named patient, from an FDA-registered maker, until the FDA decides by rule. The draft is not binding, and comments close on 13 November 2026.", "pl": "Nie ma zatwierdzonego leku. 30 października 2026 ministerstwo zdrowia USA (HHS) opublikowało projekt zasad: nie zamierza ścigać aptek i lekarzy, którzy przygotują go na receptę dla konkretnej osoby z substancji od producenta zarejestrowanego w FDA, dopóki FDA nie zdecyduje w przepisach. Projekt nie jest wiążący, a uwagi można zgłaszać do 13 listopada 2026." }, "source": "https://www.federalregister.gov/documents/2026/10/30/2026-22192/enforcement-discretion-policy-regarding-503a-compounding-using-certain-peptide-bulk-drug-substances", "checked": null } ], "research_counts": { "pubmed": 234, "pubmed_random_groups": 0, "clinicaltrials_gov": 4, "as_of": "2026-11-01T00:00:00.000Z" } }, { "slug": "cagrilintide", "url": "https://graded.pl/substances/cagrilintide", "names": { "primary": "Cagrilintide", "primary_pl": "Kagrilintyd", "aliases": [ "CagriSema (with semaglutide)", "AM833" ] }, "class": "amylin-analogue", "lifecycle": "investigational", "status": "draft", "summary": { "en": "A substance that mimics amylin, a fullness hormone. Still being studied, alone and with semaglutide. Not approved in the EU or US.", "pl": "Substancja naśladująca amylinę, hormon sytości. Wciąż w badaniach, sama i razem z semaglutydem. Nie jest dopuszczona w UE ani w USA." }, "last_reviewed": null, "wada": { "status": "s0-risk", "class": null, "list_year": 2026, "source": "https://zoek.officielebekendmakingen.nl/trb-2026-25.html" }, "safety": "partial", "risk_of_fakes": "unknown", "grades": [ { "goal": "fat-loss", "grade": "B", "direction": "benefit", "modifiers": [ "sponsor-funded" ], "studies": [ "pmid:34798060", "pmid:40544433" ], "reason": { "en": "Weight fell 6.0% to 10.8%, and 3.0% on placebo, in an early study. In a large study the mix with semaglutide reached 20.4% against 3.0%, but that is a result for the mix.", "pl": "Masa spadła o 6,0–10,8%, a na placebo o 3,0% we wczesnym badaniu. W dużym badaniu połączenie z semaglutydem dało 20,4%, a placebo 3,0%, ale to wynik połączenia." } } ], "legal": [ { "where": "PL", "status": "unauthorized", "summary": { "en": "The European medicines database (EMA) lists no such medicine in Poland (9 October 2026). The Polish register was down, so we could not check it directly.", "pl": "W europejskiej bazie leków EMA nie ma takiego leku w Polsce (stan na 9 października 2026). Polski rejestr nie działał, więc nie sprawdziliśmy tego bezpośrednio." }, "source": "https://www.ema.europa.eu/en/documents/other/article-57-product-data_en.xlsx", "checked": null }, { "where": "EU", "status": "unauthorized", "summary": { "en": "The European medicines database (EMA), which covers EU and national approvals, lists no such medicine (9 October 2026).", "pl": "W europejskiej bazie leków EMA, która obejmuje pozwolenia unijne i krajowe, nie ma takiego leku (stan na 9 października 2026)." }, "source": "https://www.ema.europa.eu/en/documents/other/article-57-product-data_en.xlsx", "checked": null }, { "where": "US", "status": "unauthorized", "summary": { "en": "The FDA drug register has no such medicine.", "pl": "W rejestrze leków FDA nie ma takiego leku." }, "source": "https://www.accessdata.fda.gov/scripts/cder/daf/", "checked": null } ], "research_counts": { "pubmed": 124, "pubmed_random_groups": 15, "clinicaltrials_gov": 44, "as_of": "2026-11-01T00:00:00.000Z" } }, { "slug": "cardarine", "url": "https://graded.pl/substances/cardarine", "names": { "primary": "Cardarine", "primary_pl": "Kardaryna", "aliases": [ "GW501516", "GW1516", "endurobol" ] }, "class": "ppar-agonist", "lifecycle": "abandoned", "status": "draft", "summary": { "en": "A substance that affects how the body uses fat (GW501516). Work on it as a medicine was stopped. No such medicine exists.", "pl": "Substancja wpływająca na to, jak organizm zużywa tłuszcz (GW501516). Prace nad nią jako lekiem przerwano. Nie ma takiego leku." }, "last_reviewed": null, "wada": { "status": "prohibited", "class": "S4.4.1", "list_year": 2026, "source": "https://zoek.officielebekendmakingen.nl/trb-2026-25.html" }, "safety": "alert", "risk_of_fakes": "high", "grades": [ { "goal": "fat-loss", "grade": "C", "direction": "unclear", "modifiers": [ "surrogate-only", "small-trials" ], "studies": [ "pmid:18024853", "pmid:17110604" ], "reason": { "en": "In a 2-week study with random groups of 6 people each, liver fat fell by 20%. Nobody measured body fat or weight loss. Work on it as a medicine stopped after cancer findings in mice.", "pl": "W 2-tygodniowym badaniu z losowaniem grup, po 6 osób w grupie, tłuszcz w wątrobie spadł o 20%. Nikt nie mierzył tłuszczu w całym ciele ani spadku masy. Prace nad lekiem przerwano po wynikach z nowotworami u myszy." } } ], "legal": [ { "where": "PL", "status": "unauthorized", "summary": { "en": "The European medicines database (EMA) lists no such medicine in Poland (9 October 2026). The Polish register was down, so we could not check it directly.", "pl": "W europejskiej bazie leków EMA nie ma takiego leku w Polsce (stan na 9 października 2026). Polski rejestr nie działał, więc nie sprawdziliśmy tego bezpośrednio." }, "source": "https://www.ema.europa.eu/en/documents/other/article-57-product-data_en.xlsx", "checked": null }, { "where": "EU", "status": "unauthorized", "summary": { "en": "The European medicines database (EMA), which covers EU and national approvals, lists no such medicine (9 October 2026).", "pl": "W europejskiej bazie leków EMA, która obejmuje pozwolenia unijne i krajowe, nie ma takiego leku (stan na 9 października 2026)." }, "source": "https://www.ema.europa.eu/en/documents/other/article-57-product-data_en.xlsx", "checked": null }, { "where": "US", "status": "unauthorized", "summary": { "en": "The FDA drug register has no such medicine.", "pl": "W rejestrze leków FDA nie ma takiego leku." }, "source": "https://www.accessdata.fda.gov/scripts/cder/daf/", "checked": null } ], "research_counts": { "pubmed": 318, "pubmed_random_groups": 4, "clinicaltrials_gov": 3, "as_of": "2026-11-01T00:00:00.000Z" } }, { "slug": "cjc-1295", "url": "https://graded.pl/substances/cjc-1295", "names": { "primary": "CJC-1295", "primary_pl": "CJC-1295", "aliases": [ "modified GRF(1-29)", "CJC-1295 DAC" ] }, "class": "ghrh-analogue", "lifecycle": "abandoned", "status": "draft", "summary": { "en": "A synthetic substance that raises growth hormone. Sold with or without DAC, an add-on that makes it last longer.", "pl": "Syntetyczna substancja podnosząca hormon wzrostu. Sprzedawana z dodatkiem DAC, który wydłuża działanie, albo bez niego." }, "last_reviewed": null, "wada": { "status": "prohibited", "class": "S2.2.4", "list_year": 2026, "source": "https://zoek.officielebekendmakingen.nl/trb-2026-25.html" }, "safety": "partial", "risk_of_fakes": "moderate", "grades": [ { "goal": "muscle-mass", "grade": "C", "direction": "unclear", "modifiers": [ "surrogate-only" ], "studies": [ "pmid:16352683" ], "reason": { "en": "In studies with random groups in healthy adults, it raised growth hormone and IGF-1, a hormone made in response to it, for several days. Nobody measured muscle or strength.", "pl": "W badaniach z losowaniem grup u zdrowych dorosłych podnosił hormon wzrostu i IGF-1, hormon wytwarzany w odpowiedzi na niego, na kilka dni. Nikt nie mierzył mięśni ani siły." } } ], "legal": [ { "where": "PL", "status": "unauthorized", "summary": { "en": "The European medicines database (EMA) lists no such medicine in Poland (9 October 2026). The Polish register was down, so we could not check it directly.", "pl": "W europejskiej bazie leków EMA nie ma takiego leku w Polsce (stan na 9 października 2026). Polski rejestr nie działał, więc nie sprawdziliśmy tego bezpośrednio." }, "source": "https://www.ema.europa.eu/en/documents/other/article-57-product-data_en.xlsx", "checked": null }, { "where": "EU", "status": "unauthorized", "summary": { "en": "The European medicines database (EMA), which covers EU and national approvals, lists no such medicine (9 October 2026).", "pl": "W europejskiej bazie leków EMA, która obejmuje pozwolenia unijne i krajowe, nie ma takiego leku (stan na 9 października 2026)." }, "source": "https://www.ema.europa.eu/en/documents/other/article-57-product-data_en.xlsx", "checked": null }, { "where": "US", "status": "unauthorized", "summary": { "en": "The FDA drug register has no such medicine.", "pl": "W rejestrze leków FDA nie ma takiego leku." }, "source": "https://www.accessdata.fda.gov/scripts/cder/daf/", "checked": null } ], "research_counts": { "pubmed": 35, "pubmed_random_groups": 1, "clinicaltrials_gov": 1, "as_of": "2026-11-01T00:00:00.000Z" } }, { "slug": "dsip", "url": "https://graded.pl/substances/dsip", "names": { "primary": "DSIP", "primary_pl": "DSIP", "aliases": [ "delta sleep-inducing peptide", "emideltide" ] }, "class": "peptide", "lifecycle": "abandoned", "status": "draft", "summary": { "en": "A peptide described in the 1970s and named for its effect on sleep in animals. No such medicine exists.", "pl": "Peptyd opisany w latach 70., nazwany tak od wpływu na sen u zwierząt. Nie ma takiego leku." }, "last_reviewed": null, "wada": { "status": "s0-risk", "class": null, "list_year": 2026, "source": "https://zoek.officielebekendmakingen.nl/trb-2026-25.html" }, "safety": "unknown", "risk_of_fakes": "unknown", "grades": [], "legal": [ { "where": "PL", "status": "unauthorized", "summary": { "en": "The European medicines database (EMA) lists no such medicine in Poland (9 October 2026). The Polish register was down, so we could not check it directly.", "pl": "W europejskiej bazie leków EMA nie ma takiego leku w Polsce (stan na 9 października 2026). Polski rejestr nie działał, więc nie sprawdziliśmy tego bezpośrednio." }, "source": "https://www.ema.europa.eu/en/documents/other/article-57-product-data_en.xlsx", "checked": null }, { "where": "EU", "status": "unauthorized", "summary": { "en": "The European medicines database (EMA), which covers EU and national approvals, lists no such medicine (9 October 2026).", "pl": "W europejskiej bazie leków EMA, która obejmuje pozwolenia unijne i krajowe, nie ma takiego leku (stan na 9 października 2026)." }, "source": "https://www.ema.europa.eu/en/documents/other/article-57-product-data_en.xlsx", "checked": null }, { "where": "US", "status": "unauthorized", "summary": { "en": "No approved medicine. FDA advisers discussed on 23–24 July 2026 whether pharmacies could make it to order.", "pl": "Nie ma zatwierdzonego leku. Doradcy FDA omawiali 23–24 lipca 2026, czy apteki mogłyby go przygotowywać na zamówienie." }, "source": "https://www.federalregister.gov/documents/2026/04/16/2026-07361/pharmacy-compounding-advisory-committee-notice-of-meeting-establishment-of-a-public-docket-request", "checked": null } ], "research_counts": { "pubmed": 463, "pubmed_random_groups": 6, "clinicaltrials_gov": 1, "as_of": "2026-11-01T00:00:00.000Z" } }, { "slug": "epitalon", "url": "https://graded.pl/substances/epitalon", "names": { "primary": "Epitalon", "primary_pl": "Epitalon", "aliases": [ "epithalon", "Ala-Glu-Asp-Gly", "AEDG" ] }, "class": "peptide", "lifecycle": "preclinical", "status": "draft", "summary": { "en": "A synthetic peptide based on a pineal gland extract. No studies with random groups and no approved medicine in the EU or US.", "pl": "Syntetyczny peptyd oparty na wyciągu z szyszynki. Nie ma badań z losowaniem grup ani dopuszczonego leku w UE i USA." }, "last_reviewed": null, "wada": { "status": "s0-risk", "class": null, "list_year": 2026, "source": "https://zoek.officielebekendmakingen.nl/trb-2026-25.html" }, "safety": "unknown", "risk_of_fakes": "unknown", "grades": [ { "goal": "longevity", "grade": "D", "direction": "unclear", "modifiers": [], "studies": [ "pmid:11087911" ], "reason": { "en": "Fruit flies lived 11% to 16% longer. There are no studies with random groups in people.", "pl": "Muszki owocowe żyły o 11–16% dłużej. Nie ma badań z losowaniem grup na ludziach." } } ], "legal": [ { "where": "PL", "status": "unauthorized", "summary": { "en": "The European medicines database (EMA) lists no such medicine in Poland (9 October 2026). The Polish register was down, so we could not check it directly.", "pl": "W europejskiej bazie leków EMA nie ma takiego leku w Polsce (stan na 9 października 2026). Polski rejestr nie działał, więc nie sprawdziliśmy tego bezpośrednio." }, "source": "https://www.ema.europa.eu/en/documents/other/article-57-product-data_en.xlsx", "checked": null }, { "where": "EU", "status": "unauthorized", "summary": { "en": "The European medicines database (EMA), which covers EU and national approvals, lists no such medicine (9 October 2026).", "pl": "W europejskiej bazie leków EMA, która obejmuje pozwolenia unijne i krajowe, nie ma takiego leku (stan na 9 października 2026)." }, "source": "https://www.ema.europa.eu/en/documents/other/article-57-product-data_en.xlsx", "checked": null }, { "where": "US", "status": "unauthorized", "summary": { "en": "No approved medicine. On 30 October 2026 the US health department (HHS) published a draft policy: it does not plan to act against pharmacies and doctors that make it on a prescription for a named patient, from an FDA-registered maker, until the FDA decides by rule. The draft is not binding, and comments close on 13 November 2026.", "pl": "Nie ma zatwierdzonego leku. 30 października 2026 ministerstwo zdrowia USA (HHS) opublikowało projekt zasad: nie zamierza ścigać aptek i lekarzy, którzy przygotują go na receptę dla konkretnej osoby z substancji od producenta zarejestrowanego w FDA, dopóki FDA nie zdecyduje w przepisach. Projekt nie jest wiążący, a uwagi można zgłaszać do 13 listopada 2026." }, "source": "https://www.federalregister.gov/documents/2026/10/30/2026-22192/enforcement-discretion-policy-regarding-503a-compounding-using-certain-peptide-bulk-drug-substances", "checked": null } ], "research_counts": { "pubmed": 123, "pubmed_random_groups": 0, "clinicaltrials_gov": 1, "as_of": "2026-11-01T00:00:00.000Z" } }, { "slug": "ghk-cu", "url": "https://graded.pl/substances/ghk-cu", "names": { "primary": "GHK-Cu", "primary_pl": "GHK-Cu", "aliases": [ "copper peptide", "copper tripeptide-1" ] }, "class": "peptide", "lifecycle": "cosmetic", "status": "draft", "summary": { "en": "A short peptide carrying copper, used in skin care. No injectable medicine in the EU or US.", "pl": "Krótki peptyd z miedzią, stosowany w kosmetykach. Nie ma leku w zastrzykach w UE ani w USA." }, "last_reviewed": null, "wada": { "status": "s0-risk", "class": null, "list_year": 2026, "source": "https://zoek.officielebekendmakingen.nl/trb-2026-25.html" }, "safety": "unknown", "risk_of_fakes": "moderate", "grades": [ { "goal": "recovery", "grade": "C", "direction": "no_benefit", "modifiers": [ "indirect-population" ], "studies": [ "pmid:16847171" ], "reason": { "en": "A study of 13 people after a laser skin treatment found no clear improvement in measurements. It tested use on the skin, not injections.", "pl": "Badanie 13 osób po laserowym zabiegu na skórę nie wykazało wyraźnej poprawy w pomiarach. Dotyczyło stosowania na skórę, a nie zastrzyków." } } ], "legal": [ { "where": "PL", "status": "unauthorized", "summary": { "en": "The European medicines database (EMA) lists no such medicine in Poland (9 October 2026). The Polish register was down, so we could not check it directly. This covers medicines, not cosmetics.", "pl": "W europejskiej bazie leków EMA nie ma takiego leku w Polsce (stan na 9 października 2026). Polski rejestr nie działał, więc nie sprawdziliśmy tego bezpośrednio. Dotyczy leków, a nie kosmetyków." }, "source": "https://www.ema.europa.eu/en/documents/other/article-57-product-data_en.xlsx", "checked": null }, { "where": "EU", "status": "unauthorized", "summary": { "en": "The European medicines database (EMA), which covers EU and national approvals, lists no such medicine (9 October 2026). This covers medicines, not cosmetics.", "pl": "W europejskiej bazie leków EMA, która obejmuje pozwolenia unijne i krajowe, nie ma takiego leku (stan na 9 października 2026). Dotyczy leków, a nie kosmetyków." }, "source": "https://www.ema.europa.eu/en/documents/other/article-57-product-data_en.xlsx", "checked": null }, { "where": "US", "status": "unauthorized", "summary": { "en": "The FDA drug register has no such medicine.", "pl": "W rejestrze leków FDA nie ma takiego leku." }, "source": "https://www.accessdata.fda.gov/scripts/cder/daf/", "checked": null } ], "research_counts": { "pubmed": 103, "pubmed_random_groups": 1, "clinicaltrials_gov": 25, "as_of": "2026-11-01T00:00:00.000Z" } }, { "slug": "ghrp-2", "url": "https://graded.pl/substances/ghrp-2", "names": { "primary": "GHRP-2", "primary_pl": "GHRP-2", "aliases": [ "pralmorelin" ] }, "class": "gh-secretagogue", "lifecycle": "approved-elsewhere", "status": "draft", "summary": { "en": "A peptide that raises growth hormone. Japan uses it to test for a shortage of that hormone. Not approved in the EU or US.", "pl": "Peptyd podnoszący hormon wzrostu. W Japonii służy do badania niedoboru tego hormonu. Nie jest dopuszczony w UE ani w USA." }, "last_reviewed": null, "wada": { "status": "prohibited", "class": "S2.2.4", "list_year": 2026, "source": "https://zoek.officielebekendmakingen.nl/trb-2026-25.html" }, "safety": "partial", "risk_of_fakes": "high", "grades": [ { "goal": "muscle-mass", "grade": "D", "direction": "unclear", "modifiers": [ "indirect-population", "surrogate-only" ], "studies": [ "pmid:12030918" ], "reason": { "en": "One study with random groups in 33 critically ill men over 5 days: it restored growth hormone release and IGF-1. Muscle was not measured, and the men were not healthy.", "pl": "Jedno badanie z losowaniem grup u 33 ciężko chorych mężczyzn przez 5 dni: przywrócił wydzielanie hormonu wzrostu i IGF-1. Mięśni nie mierzono, a badani nie byli zdrowi." } } ], "legal": [ { "where": "PL", "status": "unauthorized", "summary": { "en": "The European medicines database (EMA) lists no such medicine in Poland (9 October 2026). The Polish register was down, so we could not check it directly.", "pl": "W europejskiej bazie leków EMA nie ma takiego leku w Polsce (stan na 9 października 2026). Polski rejestr nie działał, więc nie sprawdziliśmy tego bezpośrednio." }, "source": "https://www.ema.europa.eu/en/documents/other/article-57-product-data_en.xlsx", "checked": null }, { "where": "EU", "status": "unauthorized", "summary": { "en": "The European medicines database (EMA), which covers EU and national approvals, lists no such medicine (9 October 2026).", "pl": "W europejskiej bazie leków EMA, która obejmuje pozwolenia unijne i krajowe, nie ma takiego leku (stan na 9 października 2026)." }, "source": "https://www.ema.europa.eu/en/documents/other/article-57-product-data_en.xlsx", "checked": null }, { "where": "US", "status": "unauthorized", "summary": { "en": "The FDA drug register has no such medicine.", "pl": "W rejestrze leków FDA nie ma takiego leku." }, "source": "https://www.accessdata.fda.gov/scripts/cder/daf/", "checked": null } ], "research_counts": { "pubmed": 223, "pubmed_random_groups": 42, "clinicaltrials_gov": 0, "as_of": "2026-11-01T00:00:00.000Z" } }, { "slug": "ghrp-6", "url": "https://graded.pl/substances/ghrp-6", "names": { "primary": "GHRP-6", "primary_pl": "GHRP-6", "aliases": [ "growth hormone-releasing peptide 6" ] }, "class": "gh-secretagogue", "lifecycle": "investigational", "status": "draft", "summary": { "en": "A peptide that raises growth hormone. Not approved in the EU or US.", "pl": "Peptyd podnoszący hormon wzrostu. Nie jest dopuszczony w UE ani w USA." }, "last_reviewed": null, "wada": { "status": "prohibited", "class": "S2.2.4", "list_year": 2026, "source": "https://zoek.officielebekendmakingen.nl/trb-2026-25.html" }, "safety": "partial", "risk_of_fakes": "high", "grades": [], "legal": [ { "where": "PL", "status": "unauthorized", "summary": { "en": "The European medicines database (EMA) lists no such medicine in Poland (9 October 2026). The Polish register was down, so we could not check it directly.", "pl": "W europejskiej bazie leków EMA nie ma takiego leku w Polsce (stan na 9 października 2026). Polski rejestr nie działał, więc nie sprawdziliśmy tego bezpośrednio." }, "source": "https://www.ema.europa.eu/en/documents/other/article-57-product-data_en.xlsx", "checked": null }, { "where": "EU", "status": "unauthorized", "summary": { "en": "The European medicines database (EMA), which covers EU and national approvals, lists no such medicine (9 October 2026).", "pl": "W europejskiej bazie leków EMA, która obejmuje pozwolenia unijne i krajowe, nie ma takiego leku (stan na 9 października 2026)." }, "source": "https://www.ema.europa.eu/en/documents/other/article-57-product-data_en.xlsx", "checked": null }, { "where": "US", "status": "unauthorized", "summary": { "en": "The FDA drug register has no such medicine.", "pl": "W rejestrze leków FDA nie ma takiego leku." }, "source": "https://www.accessdata.fda.gov/scripts/cder/daf/", "checked": null } ], "research_counts": { "pubmed": 674, "pubmed_random_groups": 21, "clinicaltrials_gov": 0, "as_of": "2026-11-01T00:00:00.000Z" } }, { "slug": "glutathione", "url": "https://graded.pl/substances/glutathione", "names": { "primary": "Glutathione", "primary_pl": "Glutation", "aliases": [ "GSH", "L-glutathione" ] }, "class": "nutrient", "lifecycle": "compounded", "status": "draft", "summary": { "en": "An antioxidant the body makes, sold as a supplement and offered as an injection to lighten skin. Injectable medicines exist in Italy. In the US it appears only in an eye rinse.", "pl": "Przeciwutleniacz wytwarzany przez organizm, sprzedawany jako suplement i oferowany w zastrzykach na rozjaśnianie skóry. We Włoszech istnieją leki w zastrzykach. W USA występuje tylko w płynie do płukania oka." }, "last_reviewed": null, "wada": { "status": "not-listed", "class": null, "list_year": 2026, "source": "https://zoek.officielebekendmakingen.nl/trb-2026-25.html" }, "safety": "partial", "risk_of_fakes": "unknown", "grades": [], "legal": [ { "where": "PL", "status": "unauthorized", "summary": { "en": "The European medicines database (EMA) lists no glutathione medicine in Poland (9 October 2026). The Polish register was down. This covers medicines, not supplements.", "pl": "W europejskiej bazie leków EMA nie ma leku z glutationem w Polsce (stan na 9 października 2026). Polski rejestr nie działał. Dotyczy leków, a nie suplementów." }, "source": "https://www.ema.europa.eu/en/documents/other/article-57-product-data_en.xlsx", "checked": null }, { "where": "EU", "status": "authorized", "summary": { "en": "No EU-wide approval. Injectable medicines, including Tationil and Ridutox, exist only in Italy (European medicines database, EMA, 9 October 2026).", "pl": "Bez pozwolenia na całą UE. Leki w zastrzykach, m.in. Tationil i Ridutox, istnieją tylko we Włoszech (europejska baza leków EMA, stan na 9 października 2026)." }, "source": "https://www.ema.europa.eu/en/documents/other/article-57-product-data_en.xlsx", "checked": null }, { "where": "US", "status": "unauthorized", "summary": { "en": "No injectable medicine. The substance appears in BSS Plus, an eye rinse.", "pl": "Nie ma leku w zastrzykach. Substancja występuje w płynie do płukania oka BSS Plus." }, "source": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=018469", "checked": null } ], "research_counts": { "pubmed": 1142, "pubmed_random_groups": 40, "clinicaltrials_gov": 42, "as_of": "2026-11-01T00:00:00.000Z" } }, { "slug": "hcg", "url": "https://graded.pl/substances/hcg", "names": { "primary": "hCG", "primary_pl": "hCG", "aliases": [ "human chorionic gonadotropin", "Pregnyl", "Ovitrelle" ] }, "class": "hormone", "lifecycle": "approved", "status": "draft", "summary": { "en": "A pregnancy hormone and prescription fertility medicine. The US label says plainly that it has not been shown to work for obesity. Approval covers only these medicines.", "pl": "Hormon ciążowy i lek na receptę w leczeniu niepłodności. Ulotka w USA mówi wprost, że nie wykazano jego działania w otyłości. Pozwolenie dotyczy tylko tych leków." }, "last_reviewed": null, "wada": { "status": "prohibited", "class": "S2.2.1", "list_year": 2026, "source": "https://zoek.officielebekendmakingen.nl/trb-2026-25.html" }, "safety": "characterised", "risk_of_fakes": "high", "grades": [ { "goal": "fat-loss", "grade": "A", "direction": "no_benefit", "modifiers": [], "studies": [ "pmid:786001", "pmid:2405506", "pmid:792477", "pmid:595585", "pmid:8527285" ], "reason": { "en": "In blinded studies from 1976 to 1990, people lost no more weight on hCG than on placebo injections with the same diet. A 1995 pooled analysis found no scientific proof that it works for obesity.", "pl": "W badaniach z lat 1976–1990, w których badani nie wiedzieli, co dostają, spadek masy po hCG był taki sam jak po zastrzykach placebo przy tej samej diecie. Analiza zbiorcza z 1995 r. nie znalazła naukowego potwierdzenia działania w otyłości." } } ], "legal": [ { "where": "PL", "status": "rx_only", "summary": { "en": "Approved in Poland as Chorapur and Zivafert, and across the EU as Ovitrelle (European medicines database, EMA, 9 October 2026).", "pl": "W Polsce dopuszczone Chorapur i Zivafert, a w całej UE Ovitrelle (europejska baza leków EMA, stan na 9 października 2026)." }, "source": "https://www.ema.europa.eu/en/documents/other/article-57-product-data_en.xlsx", "checked": null }, { "where": "EU", "status": "rx_only", "summary": { "en": "Approved across the EU as Ovitrelle. This covers that medicine only, not products sold outside pharmacies.", "pl": "Dopuszczony w całej UE jako Ovitrelle. Dotyczy to tylko tego leku, a nie produktów spoza aptek." }, "source": "https://www.ema.europa.eu/en/medicines/human/EPAR/ovitrelle", "checked": null }, { "where": "US", "status": "rx_only", "summary": { "en": "Prescription medicine (Pregnyl).", "pl": "Lek na receptę (Pregnyl)." }, "source": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=017692", "checked": null } ], "research_counts": { "pubmed": 1275, "pubmed_random_groups": 42, "clinicaltrials_gov": 58, "as_of": "2026-11-01T00:00:00.000Z" } }, { "slug": "igf-1-lr3", "url": "https://graded.pl/substances/igf-1-lr3", "names": { "primary": "IGF-1 LR3", "primary_pl": "IGF-1 LR3", "aliases": [ "Long R3 IGF-1" ] }, "class": "hormone", "lifecycle": "preclinical", "status": "draft", "summary": { "en": "A long-acting synthetic form of the hormone IGF-1. No studies with random groups. The approved IGF-1 medicine (Increlex) is a different product.", "pl": "Długo działająca, syntetyczna odmiana hormonu IGF-1. Nie ma badań z losowaniem grup. Dopuszczony lek z IGF-1 (Increlex) to inny produkt." }, "last_reviewed": null, "wada": { "status": "prohibited", "class": "S2.3", "list_year": 2026, "source": "https://zoek.officielebekendmakingen.nl/trb-2026-25.html" }, "safety": "unknown", "risk_of_fakes": "high", "grades": [ { "goal": "muscle-mass", "grade": "E", "direction": "unclear", "modifiers": [ "surrogate-only", "no-human-rct" ], "studies": [ "pmid:39679943" ], "reason": { "en": "There are no studies in people. Given for a week to unborn lambs with slowed growth, it did not raise their weight. Muscle was not measured.", "pl": "Nie ma badań na ludziach. Podawany przez tydzień płodom owiec z zahamowanym wzrostem nie zwiększył ich masy. Mięśni nie mierzono." } } ], "legal": [ { "where": "PL", "status": "unauthorized", "summary": { "en": "The European medicines database (EMA) lists no such medicine in Poland (9 October 2026). The Polish register was down, so we could not check it directly.", "pl": "W europejskiej bazie leków EMA nie ma takiego leku w Polsce (stan na 9 października 2026). Polski rejestr nie działał, więc nie sprawdziliśmy tego bezpośrednio." }, "source": "https://www.ema.europa.eu/en/documents/other/article-57-product-data_en.xlsx", "checked": null }, { "where": "EU", "status": "unauthorized", "summary": { "en": "The European medicines database (EMA), which covers EU and national approvals, lists no such medicine (9 October 2026).", "pl": "W europejskiej bazie leków EMA, która obejmuje pozwolenia unijne i krajowe, nie ma takiego leku (stan na 9 października 2026)." }, "source": "https://www.ema.europa.eu/en/documents/other/article-57-product-data_en.xlsx", "checked": null }, { "where": "US", "status": "unauthorized", "summary": { "en": "The FDA drug register has no such medicine.", "pl": "W rejestrze leków FDA nie ma takiego leku." }, "source": "https://www.accessdata.fda.gov/scripts/cder/daf/", "checked": null } ], "research_counts": { "pubmed": 99, "pubmed_random_groups": 0, "clinicaltrials_gov": 0, "as_of": "2026-11-01T00:00:00.000Z" } }, { "slug": "ipamorelin", "url": "https://graded.pl/substances/ipamorelin", "names": { "primary": "Ipamorelin", "primary_pl": "Ipamorelina", "aliases": [ "NNC 26-0161" ] }, "class": "gh-secretagogue", "lifecycle": "abandoned", "status": "draft", "summary": { "en": "A peptide that raises growth hormone. Not approved in the EU or US.", "pl": "Peptyd podnoszący hormon wzrostu. Nie jest dopuszczony w UE ani w USA." }, "last_reviewed": null, "wada": { "status": "prohibited", "class": "S2.2.4", "list_year": 2026, "source": "https://zoek.officielebekendmakingen.nl/trb-2026-25.html" }, "safety": "partial", "risk_of_fakes": "high", "grades": [ { "goal": "muscle-mass", "grade": "E", "direction": "unclear", "modifiers": [ "surrogate-only", "no-human-rct" ], "studies": [ "pmid:10373343", "pmid:39043357" ], "reason": { "en": "Nobody measured muscle. Rats grew longer bones and gained weight, and in ferrets on chemotherapy it reduced weight loss. There are no studies of muscle in people.", "pl": "Nikt nie mierzył mięśni. U szczurów rosły kości i masa ciała, a u fretek po chemioterapii lek ograniczał spadek masy. Nie ma badań mięśni u ludzi." } } ], "legal": [ { "where": "PL", "status": "unauthorized", "summary": { "en": "The European medicines database (EMA) lists no such medicine in Poland (9 October 2026). The Polish register was down, so we could not check it directly.", "pl": "W europejskiej bazie leków EMA nie ma takiego leku w Polsce (stan na 9 października 2026). Polski rejestr nie działał, więc nie sprawdziliśmy tego bezpośrednio." }, "source": "https://www.ema.europa.eu/en/documents/other/article-57-product-data_en.xlsx", "checked": null }, { "where": "EU", "status": "unauthorized", "summary": { "en": "The European medicines database (EMA), which covers EU and national approvals, lists no such medicine (9 October 2026).", "pl": "W europejskiej bazie leków EMA, która obejmuje pozwolenia unijne i krajowe, nie ma takiego leku (stan na 9 października 2026)." }, "source": "https://www.ema.europa.eu/en/documents/other/article-57-product-data_en.xlsx", "checked": null }, { "where": "US", "status": "unauthorized", "summary": { "en": "The FDA drug register has no such medicine.", "pl": "W rejestrze leków FDA nie ma takiego leku." }, "source": "https://www.accessdata.fda.gov/scripts/cder/daf/", "checked": null } ], "research_counts": { "pubmed": 51, "pubmed_random_groups": 2, "clinicaltrials_gov": 3, "as_of": "2026-11-01T00:00:00.000Z" } }, { "slug": "kisspeptin-10", "url": "https://graded.pl/substances/kisspeptin-10", "names": { "primary": "Kisspeptin-10", "primary_pl": "Kisspeptyna-10", "aliases": [ "KP-10" ] }, "class": "hormone", "lifecycle": "investigational", "status": "draft", "summary": { "en": "A natural peptide that switches on sex hormones, used in studies in people. No such medicine exists.", "pl": "Naturalny peptyd uruchamiający hormony płciowe, używany w badaniach na ludziach. Nie ma takiego leku." }, "last_reviewed": null, "wada": { "status": "prohibited", "class": "S2.2.1", "list_year": 2026, "source": "https://zoek.officielebekendmakingen.nl/trb-2026-25.html" }, "safety": "unknown", "risk_of_fakes": "unknown", "grades": [], "legal": [ { "where": "PL", "status": "unauthorized", "summary": { "en": "The European medicines database (EMA) lists no such medicine in Poland (9 October 2026). The Polish register was down, so we could not check it directly.", "pl": "W europejskiej bazie leków EMA nie ma takiego leku w Polsce (stan na 9 października 2026). Polski rejestr nie działał, więc nie sprawdziliśmy tego bezpośrednio." }, "source": "https://www.ema.europa.eu/en/documents/other/article-57-product-data_en.xlsx", "checked": null }, { "where": "EU", "status": "unauthorized", "summary": { "en": "The European medicines database (EMA), which covers EU and national approvals, lists no such medicine (9 October 2026).", "pl": "W europejskiej bazie leków EMA, która obejmuje pozwolenia unijne i krajowe, nie ma takiego leku (stan na 9 października 2026)." }, "source": "https://www.ema.europa.eu/en/documents/other/article-57-product-data_en.xlsx", "checked": null }, { "where": "US", "status": "unauthorized", "summary": { "en": "The FDA drug register has no such medicine.", "pl": "W rejestrze leków FDA nie ma takiego leku." }, "source": "https://www.accessdata.fda.gov/scripts/cder/daf/", "checked": null } ], "research_counts": { "pubmed": 318, "pubmed_random_groups": 5, "clinicaltrials_gov": 36, "as_of": "2026-11-01T00:00:00.000Z" } }, { "slug": "kpv", "url": "https://graded.pl/substances/kpv", "names": { "primary": "KPV", "primary_pl": "KPV", "aliases": [ "Lys-Pro-Val", "alpha-MSH 11-13" ] }, "class": "peptide", "lifecycle": "preclinical", "status": "draft", "summary": { "en": "A very short peptide studied in cells and animals for inflammation. No studies with random groups and no such medicine.", "pl": "Bardzo krótki peptyd badany na komórkach i zwierzętach pod kątem stanów zapalnych. Nie ma badań z losowaniem grup ani takiego leku." }, "last_reviewed": null, "wada": { "status": "s0-risk", "class": null, "list_year": 2026, "source": "https://zoek.officielebekendmakingen.nl/trb-2026-25.html" }, "safety": "unknown", "risk_of_fakes": "moderate", "grades": [], "legal": [ { "where": "PL", "status": "unauthorized", "summary": { "en": "The European medicines database (EMA) lists no such medicine in Poland (9 October 2026). The Polish register was down, so we could not check it directly.", "pl": "W europejskiej bazie leków EMA nie ma takiego leku w Polsce (stan na 9 października 2026). Polski rejestr nie działał, więc nie sprawdziliśmy tego bezpośrednio." }, "source": "https://www.ema.europa.eu/en/documents/other/article-57-product-data_en.xlsx", "checked": null }, { "where": "EU", "status": "unauthorized", "summary": { "en": "The European medicines database (EMA), which covers EU and national approvals, lists no such medicine (9 October 2026).", "pl": "W europejskiej bazie leków EMA, która obejmuje pozwolenia unijne i krajowe, nie ma takiego leku (stan na 9 października 2026)." }, "source": "https://www.ema.europa.eu/en/documents/other/article-57-product-data_en.xlsx", "checked": null }, { "where": "US", "status": "unauthorized", "summary": { "en": "No approved medicine. On 30 October 2026 the US health department (HHS) published a draft policy: it does not plan to act against pharmacies and doctors that make it on a prescription for a named patient, from an FDA-registered maker, until the FDA decides by rule. The draft is not binding, and comments close on 13 November 2026.", "pl": "Nie ma zatwierdzonego leku. 30 października 2026 ministerstwo zdrowia USA (HHS) opublikowało projekt zasad: nie zamierza ścigać aptek i lekarzy, którzy przygotują go na receptę dla konkretnej osoby z substancji od producenta zarejestrowanego w FDA, dopóki FDA nie zdecyduje w przepisach. Projekt nie jest wiążący, a uwagi można zgłaszać do 13 listopada 2026." }, "source": "https://www.federalregister.gov/documents/2026/10/30/2026-22192/enforcement-discretion-policy-regarding-503a-compounding-using-certain-peptide-bulk-drug-substances", "checked": null } ], "research_counts": { "pubmed": 46, "pubmed_random_groups": 0, "clinicaltrials_gov": 0, "as_of": "2026-11-01T00:00:00.000Z" } }, { "slug": "l-carnitine", "url": "https://graded.pl/substances/l-carnitine", "names": { "primary": "L-carnitine", "primary_pl": "L-karnityna", "aliases": [ "levocarnitine", "Carnitor" ] }, "class": "nutrient", "lifecycle": "approved", "status": "draft", "summary": { "en": "A compound that helps carry fats to where cells burn them for energy. Levocarnitine is a medicine for carnitine deficiency. Injections for weight loss or performance are a different use.", "pl": "Związek pomagający przenosić tłuszcze tam, gdzie komórki zamieniają je w energię. Lewokarnityna to lek na niedobór karnityny. Zastrzyki na odchudzanie lub wydolność to inne zastosowanie." }, "last_reviewed": null, "wada": { "status": "not-listed", "class": null, "list_year": 2026, "source": "https://zoek.officielebekendmakingen.nl/trb-2026-25.html" }, "safety": "characterised", "risk_of_fakes": "unknown", "grades": [ { "goal": "fat-loss", "grade": "C", "direction": "mixed", "modifiers": [ "inconsistent-results", "indirect-population" ], "studies": [ "pmid:10861338", "pmid:25600905", "pmid:20683173", "pmid:27335245", "pmid:32359762" ], "reason": { "en": "Results differ. One study found no change in overweight women, while pooled analyses report a small loss, about 1.33 kg in one. These are studies of supplements, not injections.", "pl": "Wyniki się różnią. Jedno badanie nie wykazało zmian u kobiet z nadwagą, a analizy zbiorcze podają niewielki spadek, w jednej około 1,33 kg. Dotyczy to suplementów, a nie zastrzyków." } } ], "legal": [ { "where": "PL", "status": "unauthorized", "summary": { "en": "The European medicines database (EMA) lists no levocarnitine medicine in Poland, but does in 11 EU countries (9 October 2026). The Polish register was down. This covers medicines, not supplements.", "pl": "W europejskiej bazie leków EMA nie ma leku z lewokarnityną w Polsce, jest w 11 krajach UE (stan na 9 października 2026). Polski rejestr nie działał. Dotyczy leków, a nie suplementów." }, "source": "https://www.ema.europa.eu/en/documents/other/article-57-product-data_en.xlsx", "checked": null }, { "where": "EU", "status": "authorized", "summary": { "en": "No EU-wide approval. Levocarnitine is approved separately in 11 EU countries, as injections in several, including Spain, Italy, the Netherlands and Greece (European medicines database, EMA, 9 October 2026). The database does not confirm use for weight loss.", "pl": "Bez pozwolenia na całą UE. Lewokarnityna jest dopuszczona osobno w 11 krajach UE, w zastrzykach m.in. w Hiszpanii, Włoszech, Holandii i Grecji (europejska baza leków EMA, stan na 9 października 2026). Baza nie potwierdza stosowania na odchudzanie." }, "source": "https://www.ema.europa.eu/en/documents/other/article-57-product-data_en.xlsx", "checked": null }, { "where": "US", "status": "rx_only", "summary": { "en": "Prescription medicine (levocarnitine).", "pl": "Lek na receptę (levocarnitine)." }, "source": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=076858", "checked": null } ], "research_counts": { "pubmed": 508, "pubmed_random_groups": 43, "clinicaltrials_gov": 314, "as_of": "2026-11-01T00:00:00.000Z" } }, { "slug": "lemon-bottle", "url": "https://graded.pl/substances/lemon-bottle", "names": { "primary": "Lemon Bottle", "primary_pl": "Lemon Bottle", "aliases": [ "lipolysis solution" ] }, "class": "blend", "lifecycle": "compounded", "status": "draft", "summary": { "en": "An injection sold as a \"fat dissolver\", labelled with riboflavin, bromelain and lecithin. The Swiss regulator calls it an illegal medicine, and its test did not find the declared ingredients. Finnish and US regulators have also acted.", "pl": "Zastrzyk sprzedawany jako „rozpuszczający tłuszcz”, z ryboflawiną, bromelainą i lecytyną na etykiecie. Szwajcarski urząd uznaje go za nielegalny lek, a jego test nie znalazł deklarowanych składników. Działały też urzędy Finlandii i USA." }, "last_reviewed": null, "wada": { "status": "not-listed", "class": null, "list_year": 2026, "source": "https://zoek.officielebekendmakingen.nl/trb-2026-25.html" }, "safety": "alert", "risk_of_fakes": "high", "grades": [], "legal": [ { "where": "PL", "status": "unauthorized", "summary": { "en": "The European medicines database (EMA) lists no medicine like this in Poland (9 October 2026). The Polish register was down, so we could not check it directly.", "pl": "W europejskiej bazie leków EMA nie ma leku o takim składzie w Polsce (stan na 9 października 2026). Polski rejestr nie działał, więc nie sprawdziliśmy tego bezpośrednio." }, "source": "https://www.ema.europa.eu/en/documents/other/article-57-product-data_en.xlsx", "checked": null }, { "where": "EU", "status": "unauthorized", "summary": { "en": "The Finnish medicines agency Fimea has warned against this product.", "pl": "Fińska agencja leków Fimea ostrzega przed tym produktem." }, "source": "https://fimea.fi/en/-/fimea-and-tukes-warn-against-the-lemon-bottle-product-intended-for-dissolving-fat", "checked": null }, { "where": "US", "status": "unauthorized", "summary": { "en": "In a March 2025 warning letter, the FDA treats it as an unapproved drug.", "pl": "W liście ostrzegawczym z marca 2025 FDA traktuje go jako niezatwierdzony lek." }, "source": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/fox-pharma-llc-699225-03032025", "checked": null } ], "research_counts": { "pubmed": 0, "pubmed_random_groups": 0, "clinicaltrials_gov": 0, "as_of": "2026-11-01T00:00:00.000Z" } }, { "slug": "lgd-4033", "url": "https://graded.pl/substances/lgd-4033", "names": { "primary": "LGD-4033", "primary_pl": "LGD-4033", "aliases": [ "ligandrol", "VK5211" ] }, "class": "sarm", "lifecycle": "investigational", "status": "draft", "summary": { "en": "A SARM still being studied. No such medicine exists, and the Polish sanitary inspectorate lists it as not allowed in supplements.", "pl": "SARM wciąż w badaniach. Nie ma takiego leku, a Główny Inspektorat Sanitarny wymienia go wśród substancji niedozwolonych w suplementach." }, "last_reviewed": null, "wada": { "status": "prohibited", "class": "S1.2", "list_year": 2026, "source": "https://zoek.officielebekendmakingen.nl/trb-2026-25.html" }, "safety": "alert", "risk_of_fakes": "high", "grades": [ { "goal": "muscle-mass", "grade": "B", "direction": "benefit", "modifiers": [], "studies": [ "pmid:22459616" ], "reason": { "en": "One 21-day study of 76 healthy men. Body mass without fat rose and fat did not change. We found nothing longer.", "pl": "Jedno 21-dniowe badanie 76 zdrowych mężczyzn. Masa ciała bez tłuszczu wzrosła, a tłuszcz się nie zmienił. Nie znaleźliśmy niczego dłuższego." } } ], "legal": [ { "where": "PL", "status": "unauthorized", "summary": { "en": "No approval found. The Polish sanitary inspectorate lists SARMs as not allowed in food supplements.", "pl": "Nie znaleziono pozwolenia. Główny Inspektorat Sanitarny wymienia SARM-y jako niedozwolone w suplementach diety." }, "source": "https://www.gov.pl/web/gis/zespol-do-spraw-suplementow-diety", "checked": null }, { "where": "EU", "status": "unauthorized", "summary": { "en": "The European medicines database (EMA), which covers EU and national approvals, lists no such medicine (9 October 2026).", "pl": "W europejskiej bazie leków EMA, która obejmuje pozwolenia unijne i krajowe, nie ma takiego leku (stan na 9 października 2026)." }, "source": "https://www.ema.europa.eu/en/documents/other/article-57-product-data_en.xlsx", "checked": null }, { "where": "US", "status": "unauthorized", "summary": { "en": "The FDA drug register has no such medicine.", "pl": "W rejestrze leków FDA nie ma takiego leku." }, "source": "https://www.accessdata.fda.gov/scripts/cder/daf/", "checked": null } ], "research_counts": { "pubmed": 52, "pubmed_random_groups": 1, "clinicaltrials_gov": 1, "as_of": "2026-11-01T00:00:00.000Z" } }, { "slug": "lipo-c", "url": "https://graded.pl/substances/lipo-c", "names": { "primary": "Lipo-C", "primary_pl": "Lipo-C", "aliases": [ "lipotropic injection", "MIC injection" ] }, "class": "nutrient", "lifecycle": "compounded", "status": "draft", "summary": { "en": "A mix of vitamins and amino acids injected for weight loss. The contents vary by maker. We found no studies.", "pl": "Mieszanka witamin i aminokwasów w zastrzykach, sprzedawana na odchudzanie. Skład zależy od producenta. Nie znaleźliśmy badań." }, "last_reviewed": null, "wada": { "status": "not-listed", "class": null, "list_year": 2026, "source": "https://zoek.officielebekendmakingen.nl/trb-2026-25.html" }, "safety": "unknown", "risk_of_fakes": "unknown", "grades": [], "legal": [ { "where": "PL", "status": "unauthorized", "summary": { "en": "The European medicines database (EMA) lists no medicine like this in Poland (9 October 2026). The Polish register was down, so we could not check it directly.", "pl": "W europejskiej bazie leków EMA nie ma leku o takim składzie w Polsce (stan na 9 października 2026). Polski rejestr nie działał, więc nie sprawdziliśmy tego bezpośrednio." }, "source": "https://www.ema.europa.eu/en/documents/other/article-57-product-data_en.xlsx", "checked": null }, { "where": "EU", "status": "unauthorized", "summary": { "en": "The European medicines database (EMA), which covers EU and national approvals, lists no medicine like this (9 October 2026).", "pl": "W europejskiej bazie leków EMA, która obejmuje pozwolenia unijne i krajowe, nie ma leku o takim składzie (stan na 9 października 2026)." }, "source": "https://www.ema.europa.eu/en/documents/other/article-57-product-data_en.xlsx", "checked": null }, { "where": "US", "status": "unauthorized", "summary": { "en": "The FDA drug register has no such medicine.", "pl": "W rejestrze leków FDA nie ma takiego leku." }, "source": "https://www.accessdata.fda.gov/scripts/cder/daf/", "checked": null } ], "research_counts": { "pubmed": 0, "pubmed_random_groups": 0, "clinicaltrials_gov": 0, "as_of": "2026-11-01T00:00:00.000Z" } }, { "slug": "melanotan-1", "url": "https://graded.pl/substances/melanotan-1", "names": { "primary": "Melanotan 1", "primary_pl": "Melanotan 1", "aliases": [ "afamelanotide", "Scenesse" ] }, "class": "melanocortin-agonist", "lifecycle": "approved", "status": "draft", "summary": { "en": "Afamelanotide is approved only as the Scenesse implant, for a rare condition that makes skin react badly to light. Products sold as Melanotan 1 are not this medicine.", "pl": "Afamelanotyd jest dopuszczony tylko jako implant Scenesse, przy rzadkiej chorobie, w której skóra źle reaguje na światło. Produkty sprzedawane jako Melanotan 1 to nie ten lek." }, "last_reviewed": null, "wada": { "status": "not-listed", "class": null, "list_year": 2026, "source": "https://zoek.officielebekendmakingen.nl/trb-2026-25.html" }, "safety": "characterised", "risk_of_fakes": "unknown", "grades": [], "legal": [ { "where": "PL", "status": "rx_only", "summary": { "en": "Afamelanotide is approved only as the Scenesse implant, across the EU. This does not cover vials sold as Melanotan 1.", "pl": "Afamelanotyd jest dopuszczony tylko jako implant Scenesse, w całej UE. Nie dotyczy to fiolek sprzedawanych jako Melanotan 1." }, "source": "https://www.ema.europa.eu/en/documents/other/article-57-product-data_en.xlsx", "checked": null }, { "where": "EU", "status": "rx_only", "summary": { "en": "Approved across the EU as Scenesse. This covers that medicine only, not products sold outside pharmacies.", "pl": "Dopuszczony w całej UE jako Scenesse. Dotyczy to tylko tego leku, a nie produktów spoza aptek." }, "source": "https://www.ema.europa.eu/en/medicines/human/EPAR/scenesse", "checked": null }, { "where": "US", "status": "rx_only", "summary": { "en": "Prescription medicine (Scenesse).", "pl": "Lek na receptę (Scenesse)." }, "source": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=210797", "checked": null } ], "research_counts": { "pubmed": 123, "pubmed_random_groups": 5, "clinicaltrials_gov": 24, "as_of": "2026-11-01T00:00:00.000Z" } }, { "slug": "melanotan-2", "url": "https://graded.pl/substances/melanotan-2", "names": { "primary": "Melanotan 2", "primary_pl": "Melanotan 2", "aliases": [ "melanotan II", "MT-II" ] }, "class": "melanocortin-agonist", "lifecycle": "abandoned", "status": "draft", "summary": { "en": "A synthetic substance sold for tanning. Not approved in the EU or US.", "pl": "Syntetyczna substancja sprzedawana do opalania. Nie jest dopuszczona w UE ani w USA." }, "last_reviewed": null, "wada": { "status": "s0-risk", "class": null, "list_year": 2026, "source": "https://zoek.officielebekendmakingen.nl/trb-2026-25.html" }, "safety": "alert", "risk_of_fakes": "high", "grades": [], "legal": [ { "where": "PL", "status": "unauthorized", "summary": { "en": "The European medicines database (EMA) lists no such medicine in Poland (9 October 2026). The Polish register was down, so we could not check it directly.", "pl": "W europejskiej bazie leków EMA nie ma takiego leku w Polsce (stan na 9 października 2026). Polski rejestr nie działał, więc nie sprawdziliśmy tego bezpośrednio." }, "source": "https://www.ema.europa.eu/en/documents/other/article-57-product-data_en.xlsx", "checked": null }, { "where": "EU", "status": "unauthorized", "summary": { "en": "The European medicines database (EMA), which covers EU and national approvals, lists no such medicine (9 October 2026).", "pl": "W europejskiej bazie leków EMA, która obejmuje pozwolenia unijne i krajowe, nie ma takiego leku (stan na 9 października 2026)." }, "source": "https://www.ema.europa.eu/en/documents/other/article-57-product-data_en.xlsx", "checked": null }, { "where": "US", "status": "unauthorized", "summary": { "en": "The FDA drug register has no such medicine.", "pl": "W rejestrze leków FDA nie ma takiego leku." }, "source": "https://www.accessdata.fda.gov/scripts/cder/daf/", "checked": null } ], "research_counts": { "pubmed": 199, "pubmed_random_groups": 1, "clinicaltrials_gov": 1, "as_of": "2026-11-01T00:00:00.000Z" } }, { "slug": "mk-677", "url": "https://graded.pl/substances/mk-677", "names": { "primary": "MK-677", "primary_pl": "MK-677", "aliases": [ "ibutamoren", "MK-0677" ] }, "class": "gh-secretagogue", "lifecycle": "investigational", "status": "draft", "summary": { "en": "A pill that raises growth hormone. It is not a peptide. No such medicine exists.", "pl": "Substancja w tabletkach podnosząca hormon wzrostu. Nie jest peptydem. Nie ma takiego leku." }, "last_reviewed": null, "wada": { "status": "prohibited", "class": "S2.2.4", "list_year": 2026, "source": "https://zoek.officielebekendmakingen.nl/trb-2026-25.html" }, "safety": "alert", "risk_of_fakes": "high", "grades": [ { "goal": "muscle-mass", "grade": "B", "direction": "benefit", "modifiers": [ "indirect-population" ], "studies": [ "pmid:18981485", "pmid:9467542", "pmid:9467534" ], "reason": { "en": "Body mass without fat rose in healthy older adults and obese men, and in a short study the body held on to more protein. No study tested people who train.", "pl": "Masa ciała bez tłuszczu rosła u zdrowych starszych osób i otyłych mężczyzn, a w krótkim badaniu organizm zatrzymywał więcej białka. Żadne badanie nie dotyczyło osób trenujących." } }, { "goal": "strength", "grade": "C", "direction": "no_benefit", "modifiers": [ "indirect-population" ], "studies": [ "pmid:18981485", "pmid:21067829" ], "reason": { "en": "More body mass without fat did not bring more strength or better function in older adults. A study after hip fracture was stopped early for safety reasons.", "pl": "Większa masa ciała bez tłuszczu nie dała większej siły ani sprawności u starszych osób. Badanie po złamaniu biodra przerwano wcześniej ze względów bezpieczeństwa." } } ], "legal": [ { "where": "PL", "status": "unauthorized", "summary": { "en": "The European medicines database (EMA) lists no such medicine in Poland (9 October 2026). The Polish register was down, so we could not check it directly.", "pl": "W europejskiej bazie leków EMA nie ma takiego leku w Polsce (stan na 9 października 2026). Polski rejestr nie działał, więc nie sprawdziliśmy tego bezpośrednio." }, "source": "https://www.ema.europa.eu/en/documents/other/article-57-product-data_en.xlsx", "checked": null }, { "where": "EU", "status": "unauthorized", "summary": { "en": "The European medicines database (EMA), which covers EU and national approvals, lists no such medicine (9 October 2026).", "pl": "W europejskiej bazie leków EMA, która obejmuje pozwolenia unijne i krajowe, nie ma takiego leku (stan na 9 października 2026)." }, "source": "https://www.ema.europa.eu/en/documents/other/article-57-product-data_en.xlsx", "checked": null }, { "where": "US", "status": "unauthorized", "summary": { "en": "The FDA drug register has no such medicine.", "pl": "W rejestrze leków FDA nie ma takiego leku." }, "source": "https://www.accessdata.fda.gov/scripts/cder/daf/", "checked": null } ], "research_counts": { "pubmed": 120, "pubmed_random_groups": 18, "clinicaltrials_gov": 8, "as_of": "2026-11-01T00:00:00.000Z" } }, { "slug": "mots-c", "url": "https://graded.pl/substances/mots-c", "names": { "primary": "MOTS-c", "primary_pl": "MOTS-c", "aliases": [ "mitochondrial ORF of the 12S rRNA-c" ] }, "class": "peptide", "lifecycle": "preclinical", "status": "draft", "summary": { "en": "A peptide made in mitochondria, the power plants of cells. Studied mainly in cells and animals. No such medicine exists.", "pl": "Peptyd wytwarzany w mitochondriach, czyli „elektrowniach” komórek. Badany głównie na komórkach i zwierzętach. Nie ma takiego leku." }, "last_reviewed": null, "wada": { "status": "prohibited", "class": "S4.4.1", "list_year": 2026, "source": "https://zoek.officielebekendmakingen.nl/trb-2026-25.html" }, "safety": "unknown", "risk_of_fakes": "moderate", "grades": [ { "goal": "longevity", "grade": "D", "direction": "unclear", "modifiers": [], "studies": [ "pmid:33473109" ], "reason": { "en": "Mouse studies only. Papers tagged as studies with random groups measure MOTS-c in blood and do not give it to people.", "pl": "Tylko badania na myszach. Prace oznaczone jako badania z losowaniem mierzą MOTS-c we krwi i nie podają go ludziom." } } ], "legal": [ { "where": "PL", "status": "unauthorized", "summary": { "en": "The European medicines database (EMA) lists no such medicine in Poland (9 October 2026). The Polish register was down, so we could not check it directly.", "pl": "W europejskiej bazie leków EMA nie ma takiego leku w Polsce (stan na 9 października 2026). Polski rejestr nie działał, więc nie sprawdziliśmy tego bezpośrednio." }, "source": "https://www.ema.europa.eu/en/documents/other/article-57-product-data_en.xlsx", "checked": null }, { "where": "EU", "status": "unauthorized", "summary": { "en": "The European medicines database (EMA), which covers EU and national approvals, lists no such medicine (9 October 2026).", "pl": "W europejskiej bazie leków EMA, która obejmuje pozwolenia unijne i krajowe, nie ma takiego leku (stan na 9 października 2026)." }, "source": "https://www.ema.europa.eu/en/documents/other/article-57-product-data_en.xlsx", "checked": null }, { "where": "US", "status": "unauthorized", "summary": { "en": "No approved medicine. On 30 October 2026 the US health department (HHS) published a draft policy: it does not plan to act against pharmacies and doctors that make it on a prescription for a named patient, from an FDA-registered maker, until the FDA decides by rule. The draft is not binding, and comments close on 13 November 2026.", "pl": "Nie ma zatwierdzonego leku. 30 października 2026 ministerstwo zdrowia USA (HHS) opublikowało projekt zasad: nie zamierza ścigać aptek i lekarzy, którzy przygotują go na receptę dla konkretnej osoby z substancji od producenta zarejestrowanego w FDA, dopóki FDA nie zdecyduje w przepisach. Projekt nie jest wiążący, a uwagi można zgłaszać do 13 listopada 2026." }, "source": "https://www.federalregister.gov/documents/2026/10/30/2026-22192/enforcement-discretion-policy-regarding-503a-compounding-using-certain-peptide-bulk-drug-substances", "checked": null } ], "research_counts": { "pubmed": 269, "pubmed_random_groups": 4, "clinicaltrials_gov": 6, "as_of": "2026-11-01T00:00:00.000Z" } }, { "slug": "nad-plus", "url": "https://graded.pl/substances/nad-plus", "names": { "primary": "NAD+", "primary_pl": "NAD+", "aliases": [ "nicotinamide adenine dinucleotide" ] }, "class": "nad-precursor", "lifecycle": "compounded", "status": "draft", "summary": { "en": "A compound in every cell, needed to make energy. Clinics offer it as drips and injections. No such medicine in the EU or US.", "pl": "Związek obecny w każdej komórce, potrzebny do wytwarzania energii. Kliniki oferują go w kroplówkach i zastrzykach. Nie ma takiego leku w UE ani w USA." }, "last_reviewed": null, "wada": { "status": "not-listed", "class": null, "list_year": 2026, "source": "https://zoek.officielebekendmakingen.nl/trb-2026-25.html" }, "safety": "unknown", "risk_of_fakes": "unknown", "grades": [ { "goal": "longevity", "grade": "E", "direction": "unclear", "modifiers": [ "no-human-rct" ], "studies": [ "pmid:41655607" ], "reason": { "en": "A 2026 review found no study of the effects of NAD+ itself given by drip or injection. Studies test NMN and NR, which the body turns into NAD+, and their results on health are mixed or show no effect.", "pl": "Przegląd z 2026 r. nie znalazł żadnego badania skutków samego NAD+ podawanego w kroplówce lub zastrzyku. Badania dotyczą NMN i NR, z których organizm wytwarza NAD+, a ich wyniki dla zdrowia są niejednoznaczne albo nie pokazują efektu." } } ], "legal": [ { "where": "PL", "status": "unauthorized", "summary": { "en": "The European medicines database (EMA) lists no such medicine in Poland (9 October 2026). The Polish register was down, so we could not check it directly. This covers medicines, not supplements.", "pl": "W europejskiej bazie leków EMA nie ma takiego leku w Polsce (stan na 9 października 2026). Polski rejestr nie działał, więc nie sprawdziliśmy tego bezpośrednio. Dotyczy leków, a nie suplementów." }, "source": "https://www.ema.europa.eu/en/documents/other/article-57-product-data_en.xlsx", "checked": null }, { "where": "EU", "status": "unauthorized", "summary": { "en": "The European medicines database (EMA), which covers EU and national approvals, lists no such medicine (9 October 2026). This covers medicines, not supplements.", "pl": "W europejskiej bazie leków EMA, która obejmuje pozwolenia unijne i krajowe, nie ma takiego leku (stan na 9 października 2026). Dotyczy leków, a nie suplementów." }, "source": "https://www.ema.europa.eu/en/documents/other/article-57-product-data_en.xlsx", "checked": null }, { "where": "US", "status": "unauthorized", "summary": { "en": "The FDA drug register has no such medicine.", "pl": "W rejestrze leków FDA nie ma takiego leku." }, "source": "https://www.accessdata.fda.gov/scripts/cder/daf/", "checked": null } ], "research_counts": { "pubmed": 211, "pubmed_random_groups": 1, "clinicaltrials_gov": 58, "as_of": "2026-11-01T00:00:00.000Z" } }, { "slug": "nmn", "url": "https://graded.pl/substances/nmn", "names": { "primary": "NMN", "primary_pl": "NMN", "aliases": [ "nicotinamide mononucleotide", "β-NMN" ] }, "class": "nad-precursor", "lifecycle": "investigational", "status": "draft", "summary": { "en": "A substance the body turns into NAD+. Sold as a dietary supplement.", "pl": "Substancja, z której organizm wytwarza NAD+. Sprzedawana jako suplement diety." }, "last_reviewed": null, "wada": { "status": "not-listed", "class": null, "list_year": 2026, "source": "https://zoek.officielebekendmakingen.nl/trb-2026-25.html" }, "safety": "partial", "risk_of_fakes": "unknown", "grades": [ { "goal": "longevity", "grade": "C", "direction": "unclear", "modifiers": [ "surrogate-only", "inconsistent-results" ], "studies": [ "pmid:36482258", "pmid:36797393", "pmid:33888596", "pmid:38789831", "pmid:36740954" ], "reason": { "en": "Studies are short and measure NAD in blood or fitness tests, not ageing. One found better muscle response to insulin and another found no change.", "pl": "Badania są krótkie i mierzą poziom NAD we krwi lub testy sprawności, a nie starzenie. Jedno wykazało lepszą reakcję mięśni na insulinę, inne brak zmian." } } ], "legal": [ { "where": "PL", "status": "unauthorized", "summary": { "en": "The European medicines database (EMA) lists no such medicine in Poland (9 October 2026). The Polish register was down, so we could not check it directly. This covers medicines, not supplements.", "pl": "W europejskiej bazie leków EMA nie ma takiego leku w Polsce (stan na 9 października 2026). Polski rejestr nie działał, więc nie sprawdziliśmy tego bezpośrednio. Dotyczy leków, a nie suplementów." }, "source": "https://www.ema.europa.eu/en/documents/other/article-57-product-data_en.xlsx", "checked": null }, { "where": "EU", "status": "unauthorized", "summary": { "en": "The European medicines database (EMA), which covers EU and national approvals, lists no such medicine (9 October 2026). This covers medicines, not supplements.", "pl": "W europejskiej bazie leków EMA, która obejmuje pozwolenia unijne i krajowe, nie ma takiego leku (stan na 9 października 2026). Dotyczy leków, a nie suplementów." }, "source": "https://www.ema.europa.eu/en/documents/other/article-57-product-data_en.xlsx", "checked": null }, { "where": "US", "status": "unauthorized", "summary": { "en": "The FDA drug register has no such medicine.", "pl": "W rejestrze leków FDA nie ma takiego leku." }, "source": "https://www.accessdata.fda.gov/scripts/cder/daf/", "checked": null } ], "research_counts": { "pubmed": 1555, "pubmed_random_groups": 17, "clinicaltrials_gov": 33, "as_of": "2026-11-01T00:00:00.000Z" } }, { "slug": "ostarine", "url": "https://graded.pl/substances/ostarine", "names": { "primary": "Ostarine", "primary_pl": "Ostaryna", "aliases": [ "enobosarm", "MK-2866", "GTx-024" ] }, "class": "sarm", "lifecycle": "investigational", "status": "draft", "summary": { "en": "A SARM still being studied. It raised body mass without fat in older people and cancer patients, with no clear gain in fitness in the largest studies. No such medicine exists, and products sold online are often mislabelled.", "pl": "SARM wciąż w badaniach. Zwiększał masę ciała bez tłuszczu u osób starszych i chorych na nowotwory, bez jasnej poprawy sprawności w największych badaniach. Nie ma takiego leku, a produkty z internetu często mają błędne etykiety." }, "last_reviewed": null, "wada": { "status": "prohibited", "class": "S1.2", "list_year": 2026, "source": "https://www.wada-ama.org/en/prohibited-list" }, "safety": "alert", "risk_of_fakes": "high", "grades": [ { "goal": "muscle-mass", "grade": "B", "direction": "benefit", "modifiers": [ "indirect-population", "sponsor-funded" ], "studies": [ "pmid:22031847", "pmid:23499390", "nct:NCT01355484", "nct:NCT01355497" ], "reason": { "en": "Body mass without fat rose in early and in the largest studies, but only in older adults and cancer patients. The maker paid for the studies.", "pl": "Masa ciała bez tłuszczu rosła we wczesnych i największych badaniach, ale tylko u osób starszych i chorych na nowotwory. Badania opłacił producent." } }, { "goal": "strength", "grade": "C", "direction": "mixed", "modifiers": [ "inconsistent-results", "indirect-population", "sponsor-funded" ], "studies": [ "pmid:22031847", "nct:NCT01355484", "nct:NCT01355497" ], "reason": { "en": "Physical function improved in an early study, while the two largest studies went in opposite directions. Top strength was not what they tested.", "pl": "Sprawność poprawiła się we wczesnym badaniu, a dwa największe badania dały przeciwne wyniki. Maksymalna siła nie była ich celem." } } ], "legal": [ { "where": "PL", "status": "unauthorized", "summary": { "en": "No approval. The Polish sanitary inspectorate lists ostarine, ligandrol and other SARMs as not allowed in food supplements.", "pl": "Brak pozwolenia. Główny Inspektorat Sanitarny wymienia ostarynę, ligandrol i inne SARM-y jako niedozwolone w suplementach diety." }, "source": "https://www.gov.pl/web/gis/zespol-do-spraw-suplementow-diety", "checked": null }, { "where": "EU", "status": "unauthorized", "summary": { "en": "The European medicines database (EMA), which covers EU and national approvals, lists no such medicine (9 October 2026).", "pl": "W europejskiej bazie leków EMA, która obejmuje pozwolenia unijne i krajowe, nie ma takiego leku (stan na 9 października 2026)." }, "source": "https://www.ema.europa.eu/en/documents/other/article-57-product-data_en.xlsx", "checked": null }, { "where": "US", "status": "unauthorized", "summary": { "en": "Not approved. FDA treats bodybuilding products containing SARMs as unapproved drugs.", "pl": "Niezatwierdzony. FDA traktuje produkty kulturystyczne z SARM-ami jako niezatwierdzone leki." }, "source": "https://www.fda.gov/drugs/fraudulent-products/certain-bodybuilding-products-put-consumers-risk-heart-attack-stroke-serious-liver-damage-and-more", "checked": null } ], "research_counts": { "pubmed": 108, "pubmed_random_groups": 3, "clinicaltrials_gov": 17, "as_of": "2026-11-01T00:00:00.000Z" } }, { "slug": "oxytocin", "url": "https://graded.pl/substances/oxytocin", "names": { "primary": "Oxytocin", "primary_pl": "Oksytocyna", "aliases": [ "Pitocin", "Syntocinon" ] }, "class": "hormone", "lifecycle": "approved", "status": "draft", "summary": { "en": "A natural hormone and a medicine used in childbirth. Sprays for mood or social life are a research topic, not an approved use.", "pl": "Naturalny hormon i lek stosowany przy porodzie. Aerozole na nastrój lub relacje z ludźmi to temat badań, a nie dopuszczone zastosowanie." }, "last_reviewed": null, "wada": { "status": "not-listed", "class": null, "list_year": 2026, "source": "https://zoek.officielebekendmakingen.nl/trb-2026-25.html" }, "safety": "characterised", "risk_of_fakes": "unknown", "grades": [ { "goal": "muscle-mass", "grade": "C", "direction": "benefit", "modifiers": [ "indirect-population", "small-trials" ], "studies": [ "pmid:34029521" ], "reason": { "en": "One small study with random groups, 21 older adults with obesity and weak muscles: body mass without fat rose by 2.25 kg against placebo in 8 weeks. Nobody has repeated it or tested healthy people.", "pl": "Jedno małe badanie z losowaniem grup, 21 starszych osób z otyłością i słabymi mięśniami: masa ciała bez tłuszczu wzrosła o 2,25 kg względem placebo w 8 tygodni. Nikt tego nie powtórzył ani nie badał osób zdrowych." } }, { "goal": "fat-loss", "grade": "B", "direction": "no_benefit", "modifiers": [ "indirect-population", "small-trials" ], "studies": [ "pmid:38815173", "pmid:37153702", "pmid:34029521" ], "reason": { "en": "In the largest study, 61 adults with obesity over 8 weeks, weight and body fat did not change more than on placebo. Two smaller studies in special groups found no weight loss either.", "pl": "W największym badaniu, 61 dorosłych z otyłością przez 8 tygodni, masa ciała i tłuszcz nie zmieniły się bardziej niż na placebo. Dwa mniejsze badania w szczególnych grupach też nie wykazały spadku masy." } } ], "legal": [ { "where": "PL", "status": "authorized", "summary": { "en": "Approved in Poland, including Oxytocin Grindeks and Oxytocin Richter (European medicines database, EMA, 9 October 2026). The database does not show whether a prescription is needed.", "pl": "Dopuszczona w Polsce, m.in. Oxytocin Grindeks i Oxytocin Richter (europejska baza leków EMA, stan na 9 października 2026). Baza nie pokazuje, czy potrzebna jest recepta." }, "source": "https://www.ema.europa.eu/en/documents/other/article-57-product-data_en.xlsx", "checked": null }, { "where": "EU", "status": "authorized", "summary": { "en": "No EU-wide approval. Separate national medicines in 28 countries of the European medicines database, EMA (9 October 2026).", "pl": "Bez pozwolenia na całą UE. Osobne leki krajowe w 28 krajach europejskiej bazy leków EMA (stan na 9 października 2026)." }, "source": "https://www.ema.europa.eu/en/documents/other/article-57-product-data_en.xlsx", "checked": null }, { "where": "US", "status": "rx_only", "summary": { "en": "Prescription medicine (oxytocin).", "pl": "Lek na receptę (oxytocin)." }, "source": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=018243", "checked": null } ], "research_counts": { "pubmed": 1231, "pubmed_random_groups": 445, "clinicaltrials_gov": 289, "as_of": "2026-11-01T00:00:00.000Z" } }, { "slug": "peptide-blends", "url": "https://graded.pl/substances/peptide-blends", "names": { "primary": "Peptide blends", "primary_pl": "Mieszanki peptydów", "aliases": [ "BPC-157 + TB-500", "GLOW", "KLOW", "CJC-1295 + ipamorelin" ] }, "class": "blend", "lifecycle": "compounded", "status": "draft", "summary": { "en": "Ready-mixed vials of several peptides. We found no study with random groups of BPC-157 with TB-500, so read each ingredient on its own page.", "pl": "Gotowe fiolki z kilkoma peptydami. Nie znaleźliśmy badania z losowaniem grup dla BPC-157 z TB-500, więc każdy składnik trzeba czytać osobno." }, "last_reviewed": null, "wada": { "status": "prohibited", "class": "S0, S2.3", "list_year": 2026, "source": "https://zoek.officielebekendmakingen.nl/trb-2026-25.html" }, "safety": "unknown", "risk_of_fakes": "unknown", "grades": [ { "goal": "recovery", "grade": "D", "direction": "unclear", "modifiers": [], "studies": [ "pmid:42542926" ], "reason": { "en": "In one study of tendons in rats, BPC-157 with TB-500 added nothing over either alone. There is no study of a mix in people.", "pl": "W jednym badaniu ścięgna u szczurów połączenie BPC-157 z TB-500 nie dało nic ponad każdy z nich osobno. Nie ma badań mieszanki na ludziach." } } ], "legal": [ { "where": "PL", "status": "unauthorized", "summary": { "en": "The European medicines database (EMA) lists no medicine like this in Poland (9 October 2026). The Polish register was down, so we could not check it directly.", "pl": "W europejskiej bazie leków EMA nie ma leku o takim składzie w Polsce (stan na 9 października 2026). Polski rejestr nie działał, więc nie sprawdziliśmy tego bezpośrednio." }, "source": "https://www.ema.europa.eu/en/documents/other/article-57-product-data_en.xlsx", "checked": null }, { "where": "EU", "status": "unauthorized", "summary": { "en": "The European medicines database (EMA), which covers EU and national approvals, lists no medicine like this (9 October 2026).", "pl": "W europejskiej bazie leków EMA, która obejmuje pozwolenia unijne i krajowe, nie ma leku o takim składzie (stan na 9 października 2026)." }, "source": "https://www.ema.europa.eu/en/documents/other/article-57-product-data_en.xlsx", "checked": null }, { "where": "US", "status": "unauthorized", "summary": { "en": "The FDA drug register has no such medicine.", "pl": "W rejestrze leków FDA nie ma takiego leku." }, "source": "https://www.accessdata.fda.gov/scripts/cder/daf/", "checked": null } ], "research_counts": { "pubmed": 13, "pubmed_random_groups": 0, "clinicaltrials_gov": 0, "as_of": "2026-11-01T00:00:00.000Z" } }, { "slug": "pt-141", "url": "https://graded.pl/substances/pt-141", "names": { "primary": "PT-141", "primary_pl": "PT-141", "aliases": [ "bremelanotide", "Vyleesi" ] }, "class": "melanocortin-agonist", "lifecycle": "approved", "status": "draft", "summary": { "en": "A medicine approved in the US as Vyleesi for low sex drive in women before menopause. Not approved in the EU.", "pl": "Lek dopuszczony w USA jako Vyleesi przy obniżonym popędzie u kobiet przed menopauzą. Nie jest dopuszczony w UE." }, "last_reviewed": null, "wada": { "status": "not-listed", "class": null, "list_year": 2026, "source": "https://zoek.officielebekendmakingen.nl/trb-2026-25.html" }, "safety": "characterised", "risk_of_fakes": "moderate", "grades": [], "legal": [ { "where": "PL", "status": "unauthorized", "summary": { "en": "The European medicines database (EMA) lists no such medicine in Poland (9 October 2026). The Polish register was down, so we could not check it directly.", "pl": "W europejskiej bazie leków EMA nie ma takiego leku w Polsce (stan na 9 października 2026). Polski rejestr nie działał, więc nie sprawdziliśmy tego bezpośrednio." }, "source": "https://www.ema.europa.eu/en/documents/other/article-57-product-data_en.xlsx", "checked": null }, { "where": "EU", "status": "unauthorized", "summary": { "en": "The European medicines database (EMA), which covers EU and national approvals, lists no such medicine (9 October 2026).", "pl": "W europejskiej bazie leków EMA, która obejmuje pozwolenia unijne i krajowe, nie ma takiego leku (stan na 9 października 2026)." }, "source": "https://www.ema.europa.eu/en/documents/other/article-57-product-data_en.xlsx", "checked": null }, { "where": "US", "status": "rx_only", "summary": { "en": "Prescription medicine (Vyleesi).", "pl": "Lek na receptę (Vyleesi)." }, "source": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=210557", "checked": null } ], "research_counts": { "pubmed": 113, "pubmed_random_groups": 14, "clinicaltrials_gov": 10, "as_of": "2026-11-01T00:00:00.000Z" } }, { "slug": "rad-140", "url": "https://graded.pl/substances/rad-140", "names": { "primary": "RAD-140", "primary_pl": "RAD-140", "aliases": [ "testolone", "vosilasarm" ] }, "class": "sarm", "lifecycle": "investigational", "status": "draft", "summary": { "en": "A SARM still being studied. No such medicine exists.", "pl": "SARM wciąż w badaniach. Nie ma takiego leku." }, "last_reviewed": null, "wada": { "status": "prohibited", "class": "S1.2", "list_year": 2026, "source": "https://zoek.officielebekendmakingen.nl/trb-2026-25.html" }, "safety": "alert", "risk_of_fakes": "high", "grades": [ { "goal": "muscle-mass", "grade": "D", "direction": "mixed", "modifiers": [ "no-human-rct" ], "studies": [ "pmid:40680216", "pmid:37758180" ], "reason": { "en": "Animal studies only. In young rats muscle fibres grew thicker. In female mice strength did not rise after 10 weeks and overall health got worse. The only study in people was in breast cancer and did not measure muscle.", "pl": "Tylko badania na zwierzętach. U młodych szczurów włókna mięśniowe były grubsze. U samic myszy po 10 tygodniach siła nie wzrosła, a ogólny stan zdrowia się pogorszył. Jedyne badanie na ludziach dotyczyło raka piersi i nie mierzyło mięśni." } }, { "goal": "strength", "grade": "D", "direction": "no_benefit", "modifiers": [ "no-human-rct" ], "studies": [ "pmid:37758180" ], "reason": { "en": "One study in female mice: after 10 weeks strength did not differ from the control group, and the mice were frailer and more likely to die.", "pl": "Jedno badanie na samicach myszy: po 10 tygodniach siła nie różniła się od grupy kontrolnej, a myszy były słabsze ogólnie i częściej umierały." } } ], "legal": [ { "where": "PL", "status": "unauthorized", "summary": { "en": "No approval found. The Polish sanitary inspectorate lists SARMs as not allowed in food supplements.", "pl": "Nie znaleziono pozwolenia. Główny Inspektorat Sanitarny wymienia SARM-y jako niedozwolone w suplementach diety." }, "source": "https://www.gov.pl/web/gis/zespol-do-spraw-suplementow-diety", "checked": null }, { "where": "EU", "status": "unauthorized", "summary": { "en": "The European medicines database (EMA), which covers EU and national approvals, lists no such medicine (9 October 2026).", "pl": "W europejskiej bazie leków EMA, która obejmuje pozwolenia unijne i krajowe, nie ma takiego leku (stan na 9 października 2026)." }, "source": "https://www.ema.europa.eu/en/documents/other/article-57-product-data_en.xlsx", "checked": null }, { "where": "US", "status": "unauthorized", "summary": { "en": "The FDA drug register has no such medicine.", "pl": "W rejestrze leków FDA nie ma takiego leku." }, "source": "https://www.accessdata.fda.gov/scripts/cder/daf/", "checked": null } ], "research_counts": { "pubmed": 43, "pubmed_random_groups": 0, "clinicaltrials_gov": 1, "as_of": "2026-11-01T00:00:00.000Z" } }, { "slug": "rapamycin", "url": "https://graded.pl/substances/rapamycin", "names": { "primary": "Rapamycin", "primary_pl": "Rapamycyna", "aliases": [ "sirolimus", "syrolimus", "Rapamune" ] }, "class": "mtor-inhibitor", "lifecycle": "approved", "status": "draft", "summary": { "en": "A medicine that weakens the immune system, used after transplants. Some people take it for ageing, which is not an approved use. It extends the life of mice, but short studies in people show no clear benefit. It carries serious warnings at transplant doses.", "pl": "Lek osłabiający odporność, stosowany po przeszczepach. Część osób bierze go przeciw starzeniu, choć nie jest do tego dopuszczony. Wydłuża życie myszy, ale krótkie badania na ludziach nie pokazują jasnej korzyści. Przy dawkach stosowanych po przeszczepach ma poważne ostrzeżenia." }, "last_reviewed": null, "wada": { "status": "not-listed", "class": null, "list_year": 2026, "source": "https://www.wada-ama.org/en/prohibited-list" }, "safety": "partial", "risk_of_fakes": "unknown", "grades": [ { "goal": "muscle-mass", "grade": "C", "direction": "mixed", "modifiers": [ "inconsistent-results", "small-trials" ], "studies": [ "pmid:40188830" ], "reason": { "en": "A rise in body mass without fat appeared only in women on 10 mg in one study, and it was not the main goal of that study.", "pl": "Wzrost masy ciała bez tłuszczu pojawił się tylko u kobiet przy 10 mg w jednym badaniu i nie był jego głównym celem." } }, { "goal": "strength", "grade": "B", "direction": "no_benefit", "modifiers": [ "small-trials" ], "studies": [ "pmid:41985884", "pmid:29408453" ], "reason": { "en": "Two small studies of older adults showed no gain in function, and one suggested a weaker response to training.", "pl": "Dwa małe badania osób starszych nie pokazały poprawy sprawności, a jedno sugerowało słabszą reakcję na trening." } }, { "goal": "longevity", "grade": "C", "direction": "unclear", "modifiers": [ "surrogate-only", "inconsistent-results" ], "studies": [ "pmid:19587680", "pmid:40188830", "pmid:41985884", "pmid:29408453" ], "reason": { "en": "Mice clearly lived longer. Studies in people are short, measure indirect signs and show no steady benefit.", "pl": "Myszy wyraźnie żyły dłużej. Badania na ludziach są krótkie, mierzą wskaźniki pośrednie i nie pokazują stałej korzyści." } } ], "legal": [ { "where": "PL", "status": "rx_only", "summary": { "en": "Rapamune is a prescription medicine approved across the EU. Using it for ageing is not an approved use.", "pl": "Rapamune to lek na receptę z pozwoleniem na całą UE. Stosowanie przeciw starzeniu to użycie poza zatwierdzonym celem." }, "source": "https://www.ema.europa.eu/en/medicines/human/EPAR/rapamune", "checked": null }, { "where": "EU", "status": "authorized", "summary": { "en": "Rapamune is approved after kidney transplants and for a rare lung disease.", "pl": "Rapamune jest dopuszczony po przeszczepie nerki i w rzadkiej chorobie płuc." }, "source": "https://www.ema.europa.eu/en/medicines/human/EPAR/rapamune", "checked": null }, { "where": "US", "status": "rx_only", "summary": { "en": "Prescription medicine. Using it for ageing is not an approved use.", "pl": "Lek na receptę. Stosowanie przeciw starzeniu to użycie poza zatwierdzonym celem." }, "source": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021083", "checked": null } ], "research_counts": { "pubmed": 2574, "pubmed_random_groups": 19, "clinicaltrials_gov": 86, "as_of": "2026-11-01T00:00:00.000Z" } }, { "slug": "retatrutide", "url": "https://graded.pl/substances/retatrutide", "names": { "primary": "Retatrutide", "primary_pl": "Retatrutyd", "aliases": [ "LY3437943" ] }, "class": "incretin", "lifecycle": "investigational", "status": "draft", "summary": { "en": "A substance under study that mimics three hormones linked to appetite and blood sugar. Not approved in the EU or US.", "pl": "Badana substancja naśladująca trzy hormony związane z apetytem i cukrem. Nie jest dopuszczona w UE ani w USA." }, "last_reviewed": null, "wada": { "status": "s0-risk", "class": null, "list_year": 2026, "source": "https://zoek.officielebekendmakingen.nl/trb-2026-25.html" }, "safety": "partial", "risk_of_fakes": "high", "grades": [ { "goal": "fat-loss", "grade": "A", "direction": "benefit", "modifiers": [ "sponsor-funded" ], "studies": [ "pmid:37366315", "pmid:42810372", "pmid:40609566" ], "reason": { "en": "Early and large studies show big weight loss: 18.8% at the highest dose and 5.1% on placebo, in adults with diabetes. No medicine is approved yet, and this grade says nothing about products sold online.", "pl": "Wczesne i duże badania pokazują duży spadek masy: 18,8% przy najwyższej dawce i 5,1% na placebo, u dorosłych z cukrzycą. Żaden lek nie jest jeszcze dopuszczony, a ta ocena nie mówi nic o produktach z internetu." } } ], "legal": [ { "where": "PL", "status": "unauthorized", "summary": { "en": "The European medicines database (EMA) lists no such medicine in Poland (9 October 2026). The Polish register was down, so we could not check it directly.", "pl": "W europejskiej bazie leków EMA nie ma takiego leku w Polsce (stan na 9 października 2026). Polski rejestr nie działał, więc nie sprawdziliśmy tego bezpośrednio." }, "source": "https://www.ema.europa.eu/en/documents/other/article-57-product-data_en.xlsx", "checked": null }, { "where": "EU", "status": "unauthorized", "summary": { "en": "The European medicines database (EMA), which covers EU and national approvals, lists no such medicine (9 October 2026).", "pl": "W europejskiej bazie leków EMA, która obejmuje pozwolenia unijne i krajowe, nie ma takiego leku (stan na 9 października 2026)." }, "source": "https://www.ema.europa.eu/en/documents/other/article-57-product-data_en.xlsx", "checked": null }, { "where": "US", "status": "unauthorized", "summary": { "en": "The FDA drug register has no such medicine.", "pl": "W rejestrze leków FDA nie ma takiego leku." }, "source": "https://www.accessdata.fda.gov/scripts/cder/daf/", "checked": null } ], "research_counts": { "pubmed": 213, "pubmed_random_groups": 10, "clinicaltrials_gov": 34, "as_of": "2026-11-01T00:00:00.000Z" } }, { "slug": "selank", "url": "https://graded.pl/substances/selank", "names": { "primary": "Selank", "primary_pl": "Selank", "aliases": [ "TP-7" ] }, "class": "peptide", "lifecycle": "approved-elsewhere", "status": "draft", "summary": { "en": "A synthetic peptide studied in Russia for anxiety. It is said to be registered there, which we could not confirm. Not approved in the EU or US.", "pl": "Syntetyczny peptyd badany w Rosji przy lęku. Podaje się, że jest tam zarejestrowany, ale nie udało się tego potwierdzić. Nie jest dopuszczony w UE ani w USA." }, "last_reviewed": null, "wada": { "status": "s0-risk", "class": null, "list_year": 2026, "source": "https://zoek.officielebekendmakingen.nl/trb-2026-25.html" }, "safety": "unknown", "risk_of_fakes": "moderate", "grades": [], "legal": [ { "where": "PL", "status": "unauthorized", "summary": { "en": "The European medicines database (EMA) lists no such medicine in Poland (9 October 2026). The Polish register was down, so we could not check it directly.", "pl": "W europejskiej bazie leków EMA nie ma takiego leku w Polsce (stan na 9 października 2026). Polski rejestr nie działał, więc nie sprawdziliśmy tego bezpośrednio." }, "source": "https://www.ema.europa.eu/en/documents/other/article-57-product-data_en.xlsx", "checked": null }, { "where": "EU", "status": "unauthorized", "summary": { "en": "The European medicines database (EMA), which covers EU and national approvals, lists no such medicine (9 October 2026).", "pl": "W europejskiej bazie leków EMA, która obejmuje pozwolenia unijne i krajowe, nie ma takiego leku (stan na 9 października 2026)." }, "source": "https://www.ema.europa.eu/en/documents/other/article-57-product-data_en.xlsx", "checked": null }, { "where": "US", "status": "unauthorized", "summary": { "en": "The FDA drug register has no such medicine.", "pl": "W rejestrze leków FDA nie ma takiego leku." }, "source": "https://www.accessdata.fda.gov/scripts/cder/daf/", "checked": null } ], "research_counts": { "pubmed": 68, "pubmed_random_groups": 2, "clinicaltrials_gov": 2, "as_of": "2026-11-01T00:00:00.000Z" } }, { "slug": "semaglutide", "url": "https://graded.pl/substances/semaglutide", "names": { "primary": "Semaglutide", "primary_pl": "Semaglutyd", "aliases": [ "Ozempic", "Wegovy", "Rybelsus" ] }, "class": "incretin", "lifecycle": "approved", "status": "draft", "summary": { "en": "A medicine that mimics GLP-1, a gut hormone that lowers appetite. Approved in the EU and US for type 2 diabetes and obesity. Approval covers only these medicines.", "pl": "Lek naśladujący GLP-1, hormon jelitowy zmniejszający apetyt. Dopuszczony w UE i USA na cukrzycę typu 2 i otyłość. Pozwolenie dotyczy tylko tych leków." }, "last_reviewed": null, "wada": { "status": "monitoring", "class": null, "list_year": 2026, "source": "https://www.gov.br/abcd/pt-br/composicao/atletas/substancias-e-metodos-proibidos/2026ProgramadeMonitoramento.pdf" }, "safety": "characterised", "risk_of_fakes": "high", "grades": [ { "goal": "fat-loss", "grade": "A", "direction": "benefit", "modifiers": [ "authorised-indication", "sponsor-funded" ], "studies": [ "pmid:33567185", "pmid:33667417", "pmid:33625476" ], "reason": { "en": "Weight fell by 14.9% on average, and by 2.4% on placebo, after 68 weeks. Two more large studies agree. The maker paid for the studies, which tested the pharmacy medicine.", "pl": "Masa ciała spadła średnio o 14,9%, a na placebo o 2,4% po 68 tygodniach. Dwa kolejne duże badania to potwierdzają. Badania opłacił producent i dotyczyły leku z apteki." } } ], "legal": [ { "where": "PL", "status": "rx_only", "summary": { "en": "EU-wide approvals, including Ozempic, Wegovy and Rybelsus, cover Poland. The European medicines database (EMA) shows no separate Polish product (9 October 2026).", "pl": "Pozwolenia na Ozempic, Wegovy, Rybelsus i inne obowiązują w całej UE, także w Polsce. Europejska baza leków EMA nie pokazuje osobnego leku polskiego (stan na 9 października 2026)." }, "source": "https://www.ema.europa.eu/en/documents/other/article-57-product-data_en.xlsx", "checked": null }, { "where": "EU", "status": "rx_only", "summary": { "en": "Approved across the EU as Ozempic and Wegovy. This covers that medicine only, not products sold outside pharmacies.", "pl": "Dopuszczony w całej UE jako Ozempic i Wegovy. Dotyczy to tylko tego leku, a nie produktów spoza aptek." }, "source": "https://www.ema.europa.eu/en/medicines/human/EPAR/ozempic", "checked": null }, { "where": "US", "status": "rx_only", "summary": { "en": "Prescription medicine (Wegovy).", "pl": "Lek na receptę (Wegovy)." }, "source": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=215256", "checked": null } ], "research_counts": { "pubmed": 5817, "pubmed_random_groups": 312, "clinicaltrials_gov": 793, "as_of": "2026-11-01T00:00:00.000Z" } }, { "slug": "semax", "url": "https://graded.pl/substances/semax", "names": { "primary": "Semax", "primary_pl": "Semax", "aliases": [ "ACTH(4-7)PGP" ] }, "class": "peptide", "lifecycle": "approved-elsewhere", "status": "draft", "summary": { "en": "A synthetic peptide studied mainly in Russia. It is said to be registered there, which we could not confirm. Not approved in the EU or US.", "pl": "Syntetyczny peptyd badany głównie w Rosji. Podaje się, że jest tam zarejestrowany, ale nie udało się tego potwierdzić. Nie jest dopuszczony w UE ani w USA." }, "last_reviewed": null, "wada": { "status": "s0-risk", "class": null, "list_year": 2026, "source": "https://zoek.officielebekendmakingen.nl/trb-2026-25.html" }, "safety": "unknown", "risk_of_fakes": "moderate", "grades": [], "legal": [ { "where": "PL", "status": "unauthorized", "summary": { "en": "The European medicines database (EMA) lists no such medicine in Poland (9 October 2026). The Polish register was down, so we could not check it directly.", "pl": "W europejskiej bazie leków EMA nie ma takiego leku w Polsce (stan na 9 października 2026). Polski rejestr nie działał, więc nie sprawdziliśmy tego bezpośrednio." }, "source": "https://www.ema.europa.eu/en/documents/other/article-57-product-data_en.xlsx", "checked": null }, { "where": "EU", "status": "unauthorized", "summary": { "en": "The European medicines database (EMA), which covers EU and national approvals, lists no such medicine (9 October 2026).", "pl": "W europejskiej bazie leków EMA, która obejmuje pozwolenia unijne i krajowe, nie ma takiego leku (stan na 9 października 2026)." }, "source": "https://www.ema.europa.eu/en/documents/other/article-57-product-data_en.xlsx", "checked": null }, { "where": "US", "status": "unauthorized", "summary": { "en": "No approved medicine. On 30 October 2026 the US health department (HHS) published a draft policy: it does not plan to act against pharmacies and doctors that make it on a prescription for a named patient, from an FDA-registered maker, until the FDA decides by rule. The draft is not binding, and comments close on 13 November 2026.", "pl": "Nie ma zatwierdzonego leku. 30 października 2026 ministerstwo zdrowia USA (HHS) opublikowało projekt zasad: nie zamierza ścigać aptek i lekarzy, którzy przygotują go na receptę dla konkretnej osoby z substancji od producenta zarejestrowanego w FDA, dopóki FDA nie zdecyduje w przepisach. Projekt nie jest wiążący, a uwagi można zgłaszać do 13 listopada 2026." }, "source": "https://www.federalregister.gov/documents/2026/10/30/2026-22192/enforcement-discretion-policy-regarding-503a-compounding-using-certain-peptide-bulk-drug-substances", "checked": null } ], "research_counts": { "pubmed": 210, "pubmed_random_groups": 1, "clinicaltrials_gov": 0, "as_of": "2026-11-01T00:00:00.000Z" } }, { "slug": "sermorelin", "url": "https://graded.pl/substances/sermorelin", "names": { "primary": "Sermorelin", "primary_pl": "Sermorelina", "aliases": [ "GRF(1-29)", "GHRH(1-29)", "Geref" ] }, "class": "ghrh-analogue", "lifecycle": "abandoned", "status": "draft", "summary": { "en": "A fragment of the hormone that tells the body to release growth hormone. It was sold in the US as Geref, which has since been withdrawn.", "pl": "Fragment hormonu, który każe organizmowi uwalniać hormon wzrostu. W USA sprzedawano go jako Geref, dziś ten lek jest wycofany." }, "last_reviewed": null, "wada": { "status": "prohibited", "class": "S2.2.4", "list_year": 2026, "source": "https://zoek.officielebekendmakingen.nl/trb-2026-25.html" }, "safety": "partial", "risk_of_fakes": "moderate", "grades": [ { "goal": "muscle-mass", "grade": "D", "direction": "mixed", "modifiers": [ "indirect-population", "small-trials" ], "studies": [ "pmid:9141536" ], "reason": { "en": "One small study of 19 people aged 55 to 71, without random groups: everyone got placebo first, then the drug. Body mass without fat rose in men but not in women. No study tested people who train.", "pl": "Jedno małe badanie 19 osób w wieku 55–71 lat, bez losowania grup: wszyscy dostali najpierw placebo, potem lek. Masa ciała bez tłuszczu wzrosła u mężczyzn, a u kobiet nie. Żadne badanie nie dotyczyło osób trenujących." } } ], "legal": [ { "where": "PL", "status": "unauthorized", "summary": { "en": "The European medicines database (EMA) lists no such medicine in Poland (9 October 2026). The Polish register was down, so we could not check it directly.", "pl": "W europejskiej bazie leków EMA nie ma takiego leku w Polsce (stan na 9 października 2026). Polski rejestr nie działał, więc nie sprawdziliśmy tego bezpośrednio." }, "source": "https://www.ema.europa.eu/en/documents/other/article-57-product-data_en.xlsx", "checked": null }, { "where": "EU", "status": "unauthorized", "summary": { "en": "The European medicines database (EMA), which covers EU and national approvals, lists no such medicine (9 October 2026).", "pl": "W europejskiej bazie leków EMA, która obejmuje pozwolenia unijne i krajowe, nie ma takiego leku (stan na 9 października 2026)." }, "source": "https://www.ema.europa.eu/en/documents/other/article-57-product-data_en.xlsx", "checked": null }, { "where": "US", "status": "unauthorized", "summary": { "en": "The FDA register marks Geref as withdrawn.", "pl": "W rejestrze FDA lek Geref jest oznaczony jako wycofany." }, "source": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=019863", "checked": null } ], "research_counts": { "pubmed": 366, "pubmed_random_groups": 34, "clinicaltrials_gov": 27, "as_of": "2026-11-01T00:00:00.000Z" } }, { "slug": "snap-8", "url": "https://graded.pl/substances/snap-8", "names": { "primary": "Snap-8", "primary_pl": "Snap-8", "aliases": [ "acetyl octapeptide-3" ] }, "class": "cosmetic-ingredient", "lifecycle": "cosmetic", "status": "draft", "summary": { "en": "A peptide used in anti-wrinkle creams. We found no studies under these names.", "pl": "Peptyd stosowany w kremach przeciwzmarszczkowych. Nie znaleźliśmy badań pod tymi nazwami." }, "last_reviewed": null, "wada": { "status": "not-listed", "class": null, "list_year": 2026, "source": "https://zoek.officielebekendmakingen.nl/trb-2026-25.html" }, "safety": "unknown", "risk_of_fakes": "unknown", "grades": [], "legal": [ { "where": "PL", "status": "unauthorized", "summary": { "en": "The European medicines database (EMA) lists no such medicine in Poland (9 October 2026). The Polish register was down, so we could not check it directly. This covers medicines, not cosmetics.", "pl": "W europejskiej bazie leków EMA nie ma takiego leku w Polsce (stan na 9 października 2026). Polski rejestr nie działał, więc nie sprawdziliśmy tego bezpośrednio. Dotyczy leków, a nie kosmetyków." }, "source": "https://www.ema.europa.eu/en/documents/other/article-57-product-data_en.xlsx", "checked": null }, { "where": "EU", "status": "unauthorized", "summary": { "en": "The European medicines database (EMA), which covers EU and national approvals, lists no such medicine (9 October 2026). This covers medicines, not cosmetics.", "pl": "W europejskiej bazie leków EMA, która obejmuje pozwolenia unijne i krajowe, nie ma takiego leku (stan na 9 października 2026). Dotyczy leków, a nie kosmetyków." }, "source": "https://www.ema.europa.eu/en/documents/other/article-57-product-data_en.xlsx", "checked": null }, { "where": "US", "status": "unauthorized", "summary": { "en": "The FDA drug register has no such medicine.", "pl": "W rejestrze leków FDA nie ma takiego leku." }, "source": "https://www.accessdata.fda.gov/scripts/cder/daf/", "checked": null } ], "research_counts": { "pubmed": 0, "pubmed_random_groups": 0, "clinicaltrials_gov": 0, "as_of": "2026-11-01T00:00:00.000Z" } }, { "slug": "somatropin", "url": "https://graded.pl/substances/somatropin", "names": { "primary": "Somatropin", "primary_pl": "Somatropina", "aliases": [ "human growth hormone", "HGH", "rhGH", "HGH 191AA" ] }, "class": "hormone", "lifecycle": "approved", "status": "draft", "summary": { "en": "Human growth hormone made in a lab. A prescription medicine for a shortage of this hormone and a few other conditions. Approval covers these medicines, not products sold outside pharmacies.", "pl": "Ludzki hormon wzrostu wytwarzany w laboratorium. Lek na receptę przy niedoborze tego hormonu i kilku innych chorobach. Pozwolenie dotyczy tych leków, a nie produktów spoza aptek." }, "last_reviewed": null, "wada": { "status": "prohibited", "class": "S2.2.3", "list_year": 2026, "source": "https://zoek.officielebekendmakingen.nl/trb-2026-25.html" }, "safety": "characterised", "risk_of_fakes": "high", "grades": [ { "goal": "muscle-mass", "grade": "A", "direction": "benefit", "modifiers": [], "studies": [ "pmid:8633830", "pmid:12425705", "pmid:20439575", "pmid:18347346" ], "reason": { "en": "Body mass without fat rose in older adults and amateur athletes. One study traced the rise to water, so it does not mean more muscle.", "pl": "Masa ciała bez tłuszczu rosła u osób starszych i sportowców amatorów. Jedno badanie przypisało ten wzrost wodzie, więc nie oznacza to więcej mięśni." } }, { "goal": "strength", "grade": "A", "direction": "no_benefit", "modifiers": [], "studies": [ "pmid:8633830", "pmid:12425705", "pmid:20439575", "pmid:18347346" ], "reason": { "en": "Strength did not improve in older men, and a review of healthy young adults says it may not improve. One study saw better sprinting, which faded 6 weeks after stopping.", "pl": "Siła nie wzrosła u starszych mężczyzn, a przegląd badań młodych, zdrowych osób mówi, że może nie rosnąć. Jedno badanie wykazało lepszy sprint, ale efekt zniknął 6 tygodni po odstawieniu." } } ], "legal": [ { "where": "PL", "status": "rx_only", "summary": { "en": "Approved in Poland as Genotropin and Norditropin Flexpro, and across the EU as Omnitrope (European medicines database, EMA, 9 October 2026).", "pl": "W Polsce dopuszczone Genotropin i Norditropin Flexpro, a w całej UE Omnitrope (europejska baza leków EMA, stan na 9 października 2026)." }, "source": "https://www.ema.europa.eu/en/documents/other/article-57-product-data_en.xlsx", "checked": null }, { "where": "EU", "status": "rx_only", "summary": { "en": "Approved across the EU as Omnitrope and others. This covers that medicine only, not products sold outside pharmacies.", "pl": "Dopuszczony w całej UE jako Omnitrope i inne. Dotyczy to tylko tego leku, a nie produktów spoza aptek." }, "source": "https://www.ema.europa.eu/en/medicines/human/EPAR/omnitrope", "checked": null }, { "where": "US", "status": "rx_only", "summary": { "en": "Prescription medicine (Omnitrope).", "pl": "Lek na receptę (Omnitrope)." }, "source": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021426", "checked": null } ], "research_counts": { "pubmed": 1093, "pubmed_random_groups": 119, "clinicaltrials_gov": 157, "as_of": "2026-11-01T00:00:00.000Z" } }, { "slug": "ss-31", "url": "https://graded.pl/substances/ss-31", "names": { "primary": "SS-31", "primary_pl": "SS-31", "aliases": [ "elamipretide", "Forzinity", "MTP-131", "Bendavia" ] }, "class": "peptide", "lifecycle": "approved", "status": "draft", "summary": { "en": "A peptide that acts in mitochondria, the power plants of cells. Approved in the US on a fast track as Forzinity for Barth syndrome, a rare genetic disease. Not approved in the EU.", "pl": "Peptyd działający w mitochondriach, czyli „elektrowniach” komórek. W USA dopuszczony w szybszej ścieżce jako Forzinity przy zespole Bartha, rzadkiej chorobie genetycznej. Nie jest dopuszczony w UE." }, "last_reviewed": null, "wada": { "status": "not-listed", "class": null, "list_year": 2026, "source": "https://zoek.officielebekendmakingen.nl/trb-2026-25.html" }, "safety": "partial", "risk_of_fakes": "moderate", "grades": [ { "goal": "strength", "grade": "C", "direction": "mixed", "modifiers": [ "indirect-population", "inconsistent-results" ], "studies": [ "pmid:37268435", "pmid:29500292", "pmid:32096613", "pmid:38602181" ], "reason": { "en": "A large study in a rare muscle disease found no improvement, after small studies gave unclear results. The FDA approved it on a fast track to improve muscle strength in Barth syndrome, another rare disease. None of this concerns healthy people.", "pl": "Duże badanie w rzadkiej chorobie mięśni nie wykazało poprawy, a wcześniejsze małe badania dały niejasne wyniki. FDA dopuściła lek w szybszej ścieżce do poprawy siły mięśni w zespole Bartha, innej rzadkiej chorobie. Nic z tego nie dotyczy osób zdrowych." } } ], "legal": [ { "where": "PL", "status": "unauthorized", "summary": { "en": "The European medicines database (EMA) lists no such medicine in Poland (9 October 2026). The Polish register was down, so we could not check it directly.", "pl": "W europejskiej bazie leków EMA nie ma takiego leku w Polsce (stan na 9 października 2026). Polski rejestr nie działał, więc nie sprawdziliśmy tego bezpośrednio." }, "source": "https://www.ema.europa.eu/en/documents/other/article-57-product-data_en.xlsx", "checked": null }, { "where": "EU", "status": "unauthorized", "summary": { "en": "The European medicines database (EMA), which covers EU and national approvals, lists no such medicine (9 October 2026).", "pl": "W europejskiej bazie leków EMA, która obejmuje pozwolenia unijne i krajowe, nie ma takiego leku (stan na 9 października 2026)." }, "source": "https://www.ema.europa.eu/en/documents/other/article-57-product-data_en.xlsx", "checked": null }, { "where": "US", "status": "rx_only", "summary": { "en": "Prescription medicine (Forzinity).", "pl": "Lek na receptę (Forzinity)." }, "source": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=215244", "checked": null } ], "research_counts": { "pubmed": 472, "pubmed_random_groups": 19, "clinicaltrials_gov": 29, "as_of": "2026-11-01T00:00:00.000Z" } }, { "slug": "tb-500", "url": "https://graded.pl/substances/tb-500", "names": { "primary": "TB-500", "primary_pl": "TB-500", "aliases": [ "thymosin beta-4", "Tβ4", "timbetasin" ] }, "class": "peptide", "lifecycle": "investigational", "status": "draft", "summary": { "en": "This name is used for thymosin beta-4 or a short piece of it. A test of products sold online found contents that did not match their description.", "pl": "Tą nazwą określa się tymozynę beta-4 lub jej krótki fragment. Test produktów z internetu wykazał zawartość niezgodną z opisem." }, "last_reviewed": null, "wada": { "status": "prohibited", "class": "S2.3", "list_year": 2026, "source": "https://zoek.officielebekendmakingen.nl/trb-2026-25.html" }, "safety": "unknown", "risk_of_fakes": "high", "grades": [ { "goal": "recovery", "grade": "D", "direction": "unclear", "modifiers": [], "studies": [ "pmid:42542926" ], "reason": { "en": "In one study of tendons in rats, TB-500 improved early healing. There is no study of this fragment in people.", "pl": "W jednym badaniu ścięgna u szczurów TB-500 poprawił wczesne gojenie. Nie ma badań tego fragmentu na ludziach." } } ], "legal": [ { "where": "PL", "status": "unauthorized", "summary": { "en": "The European medicines database (EMA) lists no such medicine in Poland (9 October 2026). The Polish register was down, so we could not check it directly.", "pl": "W europejskiej bazie leków EMA nie ma takiego leku w Polsce (stan na 9 października 2026). Polski rejestr nie działał, więc nie sprawdziliśmy tego bezpośrednio." }, "source": "https://www.ema.europa.eu/en/documents/other/article-57-product-data_en.xlsx", "checked": null }, { "where": "EU", "status": "unauthorized", "summary": { "en": "The European medicines database (EMA), which covers EU and national approvals, lists no such medicine (9 October 2026).", "pl": "W europejskiej bazie leków EMA, która obejmuje pozwolenia unijne i krajowe, nie ma takiego leku (stan na 9 października 2026)." }, "source": "https://www.ema.europa.eu/en/documents/other/article-57-product-data_en.xlsx", "checked": null }, { "where": "US", "status": "unauthorized", "summary": { "en": "No approved medicine. On 30 October 2026 the US health department (HHS) published a draft policy: it does not plan to act against pharmacies and doctors that make it on a prescription for a named patient, from an FDA-registered maker, until the FDA decides by rule. The draft is not binding, and comments close on 13 November 2026.", "pl": "Nie ma zatwierdzonego leku. 30 października 2026 ministerstwo zdrowia USA (HHS) opublikowało projekt zasad: nie zamierza ścigać aptek i lekarzy, którzy przygotują go na receptę dla konkretnej osoby z substancji od producenta zarejestrowanego w FDA, dopóki FDA nie zdecyduje w przepisach. Projekt nie jest wiążący, a uwagi można zgłaszać do 13 listopada 2026." }, "source": "https://www.federalregister.gov/documents/2026/10/30/2026-22192/enforcement-discretion-policy-regarding-503a-compounding-using-certain-peptide-bulk-drug-substances", "checked": null } ], "research_counts": { "pubmed": 632, "pubmed_random_groups": 3, "clinicaltrials_gov": 19, "as_of": "2026-11-01T00:00:00.000Z" } }, { "slug": "tesamorelin", "url": "https://graded.pl/substances/tesamorelin", "names": { "primary": "Tesamorelin", "primary_pl": "Tesamorelina", "aliases": [ "Egrifta", "TH9507" ] }, "class": "ghrh-analogue", "lifecycle": "approved", "status": "draft", "summary": { "en": "A medicine that raises growth hormone, approved in the US for excess belly fat in adults with HIV. The EU application was withdrawn.", "pl": "Lek podnoszący hormon wzrostu, dopuszczony w USA przy nadmiarze tłuszczu na brzuchu u dorosłych z HIV. Wniosek w UE wycofano." }, "last_reviewed": null, "wada": { "status": "prohibited", "class": "S2.2.4", "list_year": 2026, "source": "https://zoek.officielebekendmakingen.nl/trb-2026-25.html" }, "safety": "characterised", "risk_of_fakes": "moderate", "grades": [ { "goal": "fat-loss", "grade": "B", "direction": "benefit", "modifiers": [ "authorised-indication", "indirect-population" ], "studies": [ "pmid:20101189", "pmid:25038357" ], "reason": { "en": "Fat around the organs in the belly fell about 18% in people with HIV, the approved use. The effect faded after stopping. There are no data on ordinary weight loss.", "pl": "Tłuszcz wokół narządów w brzuchu spadł o około 18% u osób z HIV, czyli w dopuszczonym zastosowaniu. Efekt znikał po odstawieniu. Nie ma danych o zwykłym odchudzaniu." } } ], "legal": [ { "where": "PL", "status": "unauthorized", "summary": { "en": "The European medicines database (EMA) lists no such medicine in Poland (9 October 2026). The Polish register was down, so we could not check it directly.", "pl": "W europejskiej bazie leków EMA nie ma takiego leku w Polsce (stan na 9 października 2026). Polski rejestr nie działał, więc nie sprawdziliśmy tego bezpośrednio." }, "source": "https://www.ema.europa.eu/en/documents/other/article-57-product-data_en.xlsx", "checked": null }, { "where": "EU", "status": "unauthorized", "summary": { "en": "The application for Egrifta was withdrawn.", "pl": "Wniosek o Egrifta wycofano." }, "source": "https://www.ema.europa.eu/en/medicines/human/EPAR/egrifta", "checked": null }, { "where": "US", "status": "rx_only", "summary": { "en": "Prescription medicine (Egrifta).", "pl": "Lek na receptę (Egrifta)." }, "source": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=022505", "checked": null } ], "research_counts": { "pubmed": 95, "pubmed_random_groups": 21, "clinicaltrials_gov": 24, "as_of": "2026-11-01T00:00:00.000Z" } }, { "slug": "thymosin-alpha-1", "url": "https://graded.pl/substances/thymosin-alpha-1", "names": { "primary": "Thymosin alpha-1", "primary_pl": "Tymozyna alfa-1", "aliases": [ "thymalfasin", "Zadaxin", "Tα1" ] }, "class": "peptide", "lifecycle": "approved-elsewhere", "status": "draft", "summary": { "en": "A peptide from the thymus gland, studied mainly in chronic hepatitis B. It is a medicine in Italy (Zadaxin) and reported as one in other countries. Not in the US register.", "pl": "Peptyd z grasicy badany głównie w przewlekłym zapaleniu wątroby typu B. We Włoszech to lek Zadaxin, opisywany jako lek także w innych krajach. Nie ma go w rejestrze USA." }, "last_reviewed": null, "wada": { "status": "not-listed", "class": null, "list_year": 2026, "source": "https://zoek.officielebekendmakingen.nl/trb-2026-25.html" }, "safety": "partial", "risk_of_fakes": "unknown", "grades": [], "legal": [ { "where": "PL", "status": "unauthorized", "summary": { "en": "The European medicines database (EMA) lists no such medicine in Poland (9 October 2026). The Polish register was down, so we could not check it directly.", "pl": "W europejskiej bazie leków EMA nie ma takiego leku w Polsce (stan na 9 października 2026). Polski rejestr nie działał, więc nie sprawdziliśmy tego bezpośrednio." }, "source": "https://www.ema.europa.eu/en/documents/other/article-57-product-data_en.xlsx", "checked": null }, { "where": "EU", "status": "authorized", "summary": { "en": "No EU-wide approval. Zadaxin (thymalfasin) is approved in Italy (European medicines database, EMA, 9 October 2026).", "pl": "Bez pozwolenia na całą UE. Zadaxin (tymalfazyna) jest dopuszczony we Włoszech (europejska baza leków EMA, stan na 9 października 2026)." }, "source": "https://www.ema.europa.eu/en/documents/other/article-57-product-data_en.xlsx", "checked": null }, { "where": "US", "status": "unauthorized", "summary": { "en": "The FDA drug register has no such medicine.", "pl": "W rejestrze leków FDA nie ma takiego leku." }, "source": "https://www.accessdata.fda.gov/scripts/cder/daf/", "checked": null } ], "research_counts": { "pubmed": 890, "pubmed_random_groups": 64, "clinicaltrials_gov": 66, "as_of": "2026-11-01T00:00:00.000Z" } }, { "slug": "tirzepatide", "url": "https://graded.pl/substances/tirzepatide", "names": { "primary": "Tirzepatide", "primary_pl": "Tirzepatyd", "aliases": [ "Mounjaro", "Zepbound", "LY3298176" ] }, "class": "incretin", "lifecycle": "approved", "status": "draft", "summary": { "en": "A medicine that mimics two gut hormones, GIP and GLP-1, which affect appetite and blood sugar. Approved in the EU and US for type 2 diabetes and obesity. Approval covers only these medicines.", "pl": "Lek naśladujący dwa hormony jelitowe, GIP i GLP-1, które wpływają na apetyt i cukier. Dopuszczony w UE i USA na cukrzycę typu 2 i otyłość. Pozwolenie dotyczy tylko tych leków." }, "last_reviewed": null, "wada": { "status": "monitoring", "class": null, "list_year": 2026, "source": "https://www.gov.br/abcd/pt-br/composicao/atletas/substancias-e-metodos-proibidos/2026ProgramadeMonitoramento.pdf" }, "safety": "characterised", "risk_of_fakes": "moderate", "grades": [ { "goal": "fat-loss", "grade": "A", "direction": "benefit", "modifiers": [ "authorised-indication", "sponsor-funded" ], "studies": [ "pmid:35658024", "pmid:37385275", "pmid:38078870" ], "reason": { "en": "Weight fell by 20.9% on average at the highest dose studied, and by 3.1% on placebo, after 72 weeks. In people with diabetes it fell 12.8% to 14.7%, and 3.2% on placebo. Weight came back after stopping. The maker paid for the studies, which tested the pharmacy medicine.", "pl": "Masa ciała spadła średnio o 20,9% przy najwyższej badanej dawce, a na placebo o 3,1% po 72 tygodniach. U osób z cukrzycą spadła o 12,8–14,7%, a na placebo o 3,2%. Po odstawieniu masa wracała. Badania opłacił producent i dotyczyły leku z apteki." } } ], "legal": [ { "where": "PL", "status": "rx_only", "summary": { "en": "The EU-wide approval of Mounjaro covers Poland. The European medicines database (EMA) shows no separate Polish product (9 October 2026).", "pl": "Pozwolenie na Mounjaro obowiązuje w całej UE, także w Polsce. Europejska baza leków EMA nie pokazuje osobnego leku polskiego (stan na 9 października 2026)." }, "source": "https://www.ema.europa.eu/en/documents/other/article-57-product-data_en.xlsx", "checked": null }, { "where": "EU", "status": "rx_only", "summary": { "en": "Approved across the EU as Mounjaro. This covers that medicine only, not products sold outside pharmacies.", "pl": "Dopuszczony w całej UE jako Mounjaro. Dotyczy to tylko tego leku, a nie produktów spoza aptek." }, "source": "https://www.ema.europa.eu/en/medicines/human/EPAR/mounjaro", "checked": null }, { "where": "US", "status": "rx_only", "summary": { "en": "Prescription medicine (Mounjaro).", "pl": "Lek na receptę (Mounjaro)." }, "source": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=215866", "checked": null } ], "research_counts": { "pubmed": 2711, "pubmed_random_groups": 135, "clinicaltrials_gov": 309, "as_of": "2026-11-01T00:00:00.000Z" } }, { "slug": "vip", "url": "https://graded.pl/substances/vip", "names": { "primary": "VIP", "primary_pl": "VIP", "aliases": [ "vasoactive intestinal peptide", "aviptadil" ] }, "class": "hormone", "lifecycle": "investigational", "status": "draft", "summary": { "en": "A natural peptide that acts on blood vessels and the gut. Studied in lung disease. With phentolamine it is a licensed injection for erection problems in some European countries. Not in the US register.", "pl": "Naturalny peptyd działający na naczynia krwionośne i jelita. Badany w chorobach płuc. Z fentolaminą dopuszczony w kilku krajach Europy jako zastrzyk przy zaburzeniach erekcji. Nie ma go w rejestrze USA." }, "last_reviewed": null, "wada": { "status": "not-listed", "class": null, "list_year": 2026, "source": "https://zoek.officielebekendmakingen.nl/trb-2026-25.html" }, "safety": "partial", "risk_of_fakes": "unknown", "grades": [], "legal": [ { "where": "PL", "status": "unauthorized", "summary": { "en": "The European medicines database (EMA) lists no such medicine in Poland (9 October 2026). The Polish register was down, so we could not check it directly.", "pl": "W europejskiej bazie leków EMA nie ma takiego leku w Polsce (stan na 9 października 2026). Polski rejestr nie działał, więc nie sprawdziliśmy tego bezpośrednio." }, "source": "https://www.ema.europa.eu/en/documents/other/article-57-product-data_en.xlsx", "checked": null }, { "where": "EU", "status": "authorized", "summary": { "en": "No EU-wide approval. Aviptadil with phentolamine (Invicorp, Corpin) is approved in Denmark, Finland, France, Germany, Norway and Sweden (European medicines database, EMA, 9 October 2026). VIP alone is not.", "pl": "Bez pozwolenia na całą UE. Awiptadyl z fentolaminą (Invicorp, Corpin) jest dopuszczony w Danii, Finlandii, Francji, Niemczech, Norwegii i Szwecji (europejska baza leków EMA, stan na 9 października 2026). Sam VIP nie." }, "source": "https://www.ema.europa.eu/en/documents/other/article-57-product-data_en.xlsx", "checked": null }, { "where": "US", "status": "unauthorized", "summary": { "en": "The FDA drug register has no such medicine.", "pl": "W rejestrze leków FDA nie ma takiego leku." }, "source": "https://www.accessdata.fda.gov/scripts/cder/daf/", "checked": null } ], "research_counts": { "pubmed": 627, "pubmed_random_groups": 11, "clinicaltrials_gov": 23, "as_of": "2026-11-01T00:00:00.000Z" } }, { "slug": "vitamin-b12", "url": "https://graded.pl/substances/vitamin-b12", "names": { "primary": "Vitamin B12", "primary_pl": "Witamina B12", "aliases": [ "cyanocobalamin", "hydroxocobalamin", "methylcobalamin" ] }, "class": "nutrient", "lifecycle": "approved", "status": "draft", "summary": { "en": "A vitamin available as an injectable medicine for a shortage. Injections for energy or weight loss are a different use.", "pl": "Witamina dostępna jako lek w zastrzykach przy niedoborze. Zastrzyki na energię lub odchudzanie to inne zastosowanie." }, "last_reviewed": null, "wada": { "status": "not-listed", "class": null, "list_year": 2026, "source": "https://zoek.officielebekendmakingen.nl/trb-2026-25.html" }, "safety": "characterised", "risk_of_fakes": "unknown", "grades": [], "legal": [ { "where": "PL", "status": "authorized", "summary": { "en": "Approved as Vitaminum B12 Wzf and Sf injections, and as Cobalaxin and Energamma by mouth (European medicines database, EMA, 9 October 2026).", "pl": "Dopuszczona jako zastrzyki Vitaminum B12 Wzf i Sf oraz doustnie Cobalaxin i Energamma (europejska baza leków EMA, stan na 9 października 2026)." }, "source": "https://www.ema.europa.eu/en/documents/other/article-57-product-data_en.xlsx", "checked": null }, { "where": "EU", "status": "authorized", "summary": { "en": "Separate national medicines in 31 countries of the European medicines database, EMA (9 October 2026).", "pl": "Osobne leki krajowe w 31 krajach europejskiej bazy leków EMA (stan na 9 października 2026)." }, "source": "https://www.ema.europa.eu/en/documents/other/article-57-product-data_en.xlsx", "checked": null }, { "where": "US", "status": "rx_only", "summary": { "en": "Prescription medicine (cyanocobalamin).", "pl": "Lek na receptę (cyanocobalamin)." }, "source": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=215107", "checked": null } ], "research_counts": { "pubmed": 529, "pubmed_random_groups": 37, "clinicaltrials_gov": 143, "as_of": "2026-11-01T00:00:00.000Z" } } ] }